预约演示
更新于：2026-03-21
Sulfamethoxazole/Trimethoprim
磺胺甲噁唑/甲氧苄啶
更新于：2026-03-21
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H29N7O6S |
InChIKeyWZRJTRPJURQBRM-UHFFFAOYSA-N |
CAS号8064-90-2 |
关联
222
项与 磺胺甲噁唑/甲氧苄啶 相关的临床试验NCT07485010
A Multi-centre, Randomised Trial Comparing a Novel Combination Treatment (Arm D - Intravenous Sulbactam-durlobactam in Combination With Intravenous Ceftriaxone, Oral Amoxicillin, Oral Azithromycin and Oral Clofazimine) Versus Standard of Care Treatments for the Intensive Phase of Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to the standard treatments. It will also learn about the safety of this new combination antibiotic treatment when compared to the standard treatments. The main questions it aims to answer are:
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.
* How well does Arm D treat mycobacterium abscessus pulmonary disease?
* What side effects does Arm D cause when used to treat mycobacterium abscessus pulmonary disease? Researchers will compare Arm D to the current standard of care treatments to see if Arm D treats mycobacterium abscessus pulmonary disease better and if it will cause less side effects.
Participants will:
* Be screened and recruited to the FORMaT adaptive platform trial (NCT04310930)
* Be given Arm D for 4 weeks or standard of care treatments for 6 weeks.
* Be reviewed by the study doctors weekly for checkups and tests.
* Provide respiratory samples (sample coughed up from the chest), respond to quality-of-life questionnaires, have CT lung scans and blood tests.
开始日期2027-04-01 |
申办/合作机构 |
NCT07106125
Trial of Antibiotic Strategies for Kidney Transplant Recipients
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.
The main questions this study is asking are:
* Does TMP-SMX lower the number of UTIs in the first year after transplant?
* What side effects or problems do participants have while taking TMP-SMX?
Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.
Participants will:
* Take either TMP-SMX or a placebo pill by mouth every day for 6 months
* Have three visits to touch base with the study team about any issues
* Complete short monthly online surveys about any symptoms or side effects
* Share blood and urine test results from their regular transplant clinic visits
The main questions this study is asking are:
* Does TMP-SMX lower the number of UTIs in the first year after transplant?
* What side effects or problems do participants have while taking TMP-SMX?
Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.
Participants will:
* Take either TMP-SMX or a placebo pill by mouth every day for 6 months
* Have three visits to touch base with the study team about any issues
* Complete short monthly online surveys about any symptoms or side effects
* Share blood and urine test results from their regular transplant clinic visits
开始日期2026-11-01 |
NCT07451171
A Phase II Trial to Prevent Linear Growth Stunting and Malnutrition in Impoverished Children From a Low-Income Country by Treating Small Intestine Bacterial Overgrowth
The purpose of this Phase IIa study is to identify the most effective antibiotic regimen to treat small intestine bacterial overgrowth (SIBO) in impoverished Bangladeshi children.
开始日期2026-04-01 |
申办/合作机构 |
100 项与 磺胺甲噁唑/甲氧苄啶 相关的临床结果
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的转化医学
登录后查看更多信息
100 项与 磺胺甲噁唑/甲氧苄啶 相关的专利（医药）
登录后查看更多信息
18,458
项与 磺胺甲噁唑/甲氧苄啶 相关的文献（医药）2026-05-01·RESEARCH IN VETERINARY SCIENCE
Staphylococcus haemolyticus isolated from the Elaphurus davidianus: Pathogenicity and antimicrobial susceptibility profile
Article
作者: Li, Zhenpeng ; Han, Qingyan ; Wang, Jie ; Mu, Qian ; Yao, Wanling ; Zuo, Sihan ; Meng, Yongcheng ; Han, Mengling ; Huang, Zhen ; Zhang, Wangdong ; Hua, Yongli
Staphylococcus haemolyticus is an important zoonotic pathogen. The objective of this study was to investigate the pathogenicity of a Staphylococcus haemolyticus isolated from the blood of Elaphurus davidianus and evaluate its potential risks to public health. A combination of methods including 16S rRNA sequencing, PCR, antimicrobial susceptibility testing and mouse challenge assay was employed to systematically investigate its phylogenetic relationships, growth characteristics, virulence and antimicrobial resistance genes, LD₅₀, and antimicrobial resistance profile. The results indicated that the strain was identified as Staphylococcus haemolyticus. The LD50 of the strain in mice was determined to be 6.4 × 108 CFU/ml, and the strain caused significant pathological lesions in the heart, lung, spleen, kidney and liver of the mice. In addition, the strain harbored 8 virulence genes, including Lipase, Polyglutamic acid capsule, Uge, WbtP, Thermonuclease, Type VII secretion system, Autolysin, and Cytolysin. Meanwhile, it exhibited resistance to 18 antibiotics, such as oxacillin, ampicillin, benzylpenicillin, levofloxacin, ceftazidime, streptomycin, imipenem, minocycline, tetracycline, doxycycline, azithromycin, erythromycin, clindamycin, lincomycin, vancomycin, chloramphenicol, florfenicol, and cotrimoxazole, and harbored 12 antimicrobial resistance genes, including msrA, mphC, PC1, AAC(6')-Ie-APH(2″)-Ia, vanY gene in vanB cluster, vanY gene in vanM cluster, APH(3')-IIIa, vanT gene in vanG cluster, sepA, norC, sdrM, and dfrG. Collectively, these findings indicated that the strain possessed strong virulence and exhibited resistance to multiple antibiotics. This suggested that it posed considerable potential risks to public health. This study provides a scientific basis for further investigation into the pathogenic mechanisms, antimicrobial resistance mechanisms, and prevention and control strategies of this strain.
2026-04-01·Neurohospitalist
Subacute Combined Degeneration From Isolated Folate Deficiency Secondary to Nutrition and Co-Trimoxazole Use in a Patient With IgG4-Related Disease
Article
作者: Viswanathan, Anand ; Pongpitakmetha, Thanakit ; Amornvit, Jakkrit ; Yonpiam, Manta ; Laohapiboolrattana, Wattakorn
Subacute combined degeneration (SCD) is characterized by demyelination primarily affecting the dorsal column and lateral corticospinal tracts. It typically presents with paresthesia in the feet and progresses to involve the upper extremities. SCD is commonly associated with nutritional deficiencies, particularly deficiencies of vitamin B12, folate, or copper. Neurological disorders solely caused by isolated folate deficiency are uncommon. Classic presentations of folate deficiency include fatigue, lethargy, glossitis, diarrhea, and the gradual development of megaloblastic anemia. Early SCD diagnosis and treatment, even in the absence of hematological signs, are imperative to prevent irreversible neurological deficits and achieve favorable outcomes. We present a patient with IgG4-related disease who developed subacute sensory ataxia and generalized hyperreflexia. She was eventually diagnosed with SCD, which was attributed to isolated folate deficiency caused by critical illness-related malnutrition and concomitant co-trimoxazole use. Her clinical and neurological examination findings improved at the subsequent 2-week follow-up after effective treatment. Finally, she was able to walk and run independently. This case emphasizes the importance of early recognition of this rare presentation and prompt treatment, which can significantly contribute to better neurological outcomes.
2026-04-01·TROPICAL DOCTOR
Musculoskeletal infections caused by
Salmonella Typhi
: A series of two case reports in immunocompetent adults
Article
作者: Raina, Shweta ; Saksena, Rushika ; Sah, Palash
We report two such cases. Case 1: A 30-year-old male presented with right forearm swelling and pain; examination revealed a non-mobile, fluctuant intramuscular swelling. Case 2: A 30-year-old female had a 3-month history of midline chest pain with a mobile, fluctuant swelling over the xiphisternum. In both cases, aspirated pus showed numerous pus cells with few Gram-negative bacilli. Culture revealed non-lactose fermenting, smooth convex colonies identified as Salmonella Typhi by biochemical tests, Vitek 2 (bioMérieux), and serology. The isolates were susceptible to ceftriaxone, ciprofloxacin, azithromycin, cotrimoxazole, and ampicillin, but resistant to chloramphenicol. Both patients were immunocompetent, with no history of trauma, diabetes, or haemoglobinopathy, and responded well to antibiotic therapy. These cases highlight the need for clinical awareness of atypical presentations of
S. Typhi
osteomyelitis and the importance of timely diagnosis in endemic regions.
103
项与 磺胺甲噁唑/甲氧苄啶 相关的新闻（医药）2026-03-17
注册号：
Registration number：
ChiCTR2600120593 最近更新日期：
Date of Last Refreshed on：
2026-03-17 10:27:29 注册时间：
Date of Registration：
2026-03-17 00:00:00 注册号状态：
预注册Registration Status：
Prospective registration注册题目：
不同剂量组利妥昔单抗治疗中重度天疱疮的全国多中心、开放标签、随机对照临床研究Public title：
Different Doses of Rituximab in the Treatment of Moderate to Severe Pemphigus: A Multicenter, Open-Label, Randomized Controlled Trial注册题目简写：English Acronym：研究课题的正式科学名称：
不同剂量组利妥昔单抗治疗中重度天疱疮的全国多中心、开放标签、随机对照临床研究Scientific title：
Different Doses of Rituximab in the Treatment of Moderate to Severe Pemphigus: A Multicenter, Open-Label, Randomized Controlled Trial研究课题代号(代码)：
Study subject ID：在二级注册机构或其它机构的注册号：
The registration number of the Partner Registry or other
register：申请注册联系人：
张福仁
研究负责人：
张福仁 Applicant：
Zhang Furong
Study leader：
Zhang Furong 申请注册联系人电话：
Applicant telephone：
+86 531 87298808
研究负责人电话：
Study leader's telephone：
+86 531 87298808申请注册联系人传真 ：
Applicant Fax：
研究负责人传真：
Study leader's fax：申请注册联系人电子邮件：
Applicant E-mail：
shancaolily@163.com
研究负责人电子邮件：
Study leader's E-mail：
zhangfuren@hotmail.com申请单位网址(自愿提供)：
Applicant website(voluntary supply)：
研究负责人网址(自愿提供)：
Study leader's website(voluntary supply)：申请注册联系人通讯地址：
中国山东省济南市槐荫区经十路27397号
研究负责人通讯地址：
中国山东省济南市槐荫区经十路27397号Applicant address：
27397 Jingshi Road, Huaiyin District, Jinan, Shandong, China
Study leader's address：
27397 Jingshi Road, Huaiyin District, Jinan, Shandong, China申请注册联系人邮政编码：
Applicant postcode：
研究负责人邮政编码：
Study leader's postcode：申请人所在单位：
山东第一医科大学附属皮肤病医院Applicant's institution：
Affiliated Dermatology Hospital of Shandong First Medical University研究负责人所在单位：
山东第一医科大学附属皮肤病医院Affiliation of the Leader：
Affiliated Dermatology Hospital of Shandong First Medical University是否获伦理委员会批准：
是Approved by ethic committee：
Yes伦理委员会批件文号：
Approved No. of ethic committee：
20260302IIT001
伦理委员会批件附件：
Approved file of Ethical Committee：
查看附件View批准本研究的伦理委员会名称：
山东第一医科大学附属皮肤病医院医学伦理委员会Name of the ethic committee：
Medical Ethics Committee of Hospital for Skin Diseases, Shandong First Medical University伦理委员会批准日期：
Date of approved by ethic committee：
2026-03-02 00:00:00伦理委员会联系人：
赵伟Contact Name of the ethic committee：
Zhao Wei伦理委员会联系地址：
中国山东省济南市槐荫区经十路27397号Contact Address of the ethic committee：
27397 Jingshi Road, Huaiyin District, Jinan, Shandong, China伦理委员会联系人电话：
Contact phone of the ethic committee：
+86 531 87298817
伦理委员会联系人邮箱：
Contact email of the ethic committee：
sdpysll@163.com研究实施负责（组长）单位：
山东第一医科大学附属皮肤病医院Primary sponsor：
Affiliated Dermatology Hospital of Shandong First Medical University研究实施负责（组长）单位地址：
中国山东省济南市槐荫区经十路27397号Primary sponsor's address：
27397 Jingshi Road, Huaiyin District, Jinan, Shandong, China试验主办单位(项目批准或申办者)：
Secondary sponsor：
国家：
中国
省(直辖市)：
山东
市(区县)：
Country：
China
Province：
Shandong
City：
单位(医院)：
山东第一医科大学附属皮肤病医院
具体地址：
中国山东省济南市槐荫区经十路27397号
Institution
hospital：
Affiliated Dermatology Hospital of Shandong First Medical University
Address：
27397 Jingshi Road, Huaiyin District, Jinan, Shandong, China经费或物资来源：
自选课题（自筹）Source(s) of funding：
Self-selected topic (self-funded)研究疾病：
天疱疮 Target disease：
Pemphigus研究疾病代码：Target disease code：研究类型：
干预性研究Study type：
Interventional study研究所处阶段：
其它 Study phase：
N/A研究设计：
随机平行对照 Study design：
Parallel 研究目的：
本研究的主要目的是评价不同剂量利妥昔单抗联合系统性糖皮质激素治疗中重度天疱疮的的有效性。 Objectives of Study：
The primary objective of this study is to evaluate the efficacy of different doses of rituximab in combination with systemic glucocorticoids for the treatment of moderate to severe pemphigus.药物成份或治疗方案详述：
Description for medicine or protocol of treatment in
detail：
纳入标准：
1. 愿意签署知情同意书并且能够遵从方案的要求；
2. 年龄 18 ~ 75 周岁，性别不限；
3. 符合天疱疮诊断标准：(1) 临床表现：寻常型为皮肤/黏膜松弛性水疱、糜烂，尼氏征阳性；落叶型为脂溢部位或全身性水疱，形成油腻性鳞屑和落叶状痴皮，尼氏征阳性，通常无黏膜受累；(2) 组织病理学：寻常型：表皮内疱及基底层上棘层松解；落叶型：表皮内疱，角质层下或颗粒层棘层松解；(3) 直接免疫荧光示表皮细胞间 IgG 和/或 C3 网状沉积；(4) 酶联免疫吸附试验（ELISA）检测：寻常型：Dsg3 抗体阳性（伴或不伴抗 Dsg1 抗体阳性）；落叶型：抗 Dsg1 抗体阳性；
4. 中重度天疱疮（PDAI 评分：中度 15-45 分，重度＞45 分）；
5. 首次接受利妥昔单抗治疗；
6. 具有生育功能的女性受试者须同意在研究过程中及末次给药后的12个月内采取适当的避孕措施（例如激素类避孕药、避孕贴、宫内节育器、物理避孕）。（注：无生育功能是指已绝经至少 2 年或者已接受子宫全切除术、双侧输卵管结扎术或双侧输卵管切除术和 / 或双侧卵巢切除术，或患有先天性不孕的女性受试者）；
7. 男性受试者的配偶或伴侣为有生育功能的女性，男性受试者也必须同意在研究过程中及末次给药后的12个月内采取适当的避孕措施，且在这期间男性受试者不会捐献精子；
8. 研究者判断患者可以耐受利妥昔单抗的治疗；Inclusion criteria
1. Willing and able to provide written Informed Consent Form (ICF) and comply with all protocol-specified requirements.
2. Male or female patients, aged 18 to 75 years (inclusive).
3. Diagnosis of Pemphigus Vulgaris (PV) or Pemphigus Foliaceus (PF) meeting the following criteria: (1) Clinical presentation: For PV, presence of flaccid blisters or erosions on the skin and/or mucous membranes with a positive Nikolsky sign; for PF, presence of blisters in seborrheic areas or generalized distribution, evolving into greasy scales and foliaceous crusts, with a positive Nikolsky sign and typically no mucosal involvement. (2) Histopathology: For PV, intraepidermal blisters with suprabasal acantholysis; for PF, intraepidermal blisters with subcorneal or granular layer acantholysis. (3) Direct Immunofluorescence (DIF): Reticular (intercellular) deposition of IgG and/or C3 within the epidermis. (4) Enzyme-Linked Immunosorbent Assay (ELISA): For PV, positive for anti-Desmoglein 3 (Dsg3) antibodies (with or without positive anti-Dsg1); for PF, positive for anti-Dsg1 antibodies.
4. Moderate-to-severe pemphigus, defined by a Pemphigus Disease Area Index (PDAI) score: moderate (15–45 points) or severe (>45 points).
5. Rituximab-naïve (no prior exposure to rituximab therapy).
6. Female subjects of childbearing potential (WOCBP) must agree to use highly effective contraception (e.g., hormonal contraceptives, contraceptive patches, intrauterine devices, or barrier methods) throughout the study and for at least 12 months following the final dose. (Note: "Non-childbearing potential" is defined as being postmenopausal for at least 2 years, or having undergone total hysterectomy, bilateral salpingectomy, bilateral tubal ligation, bilateral oophorectomy, or having congenital infertility).
7. Male subjects with a female partner of childbearing potential must agree to use adequate contraception throughout the study and for 12 months after the final dose, and must refrain from sperm donation during this period.
8. In the investigator's clinical judgment, the patient is deemed capable of tolerating rituximab therapy.排除标准：
1. 患者年龄＜18 或＞75 周岁；
2. 存在利妥昔单抗/吗替麦考酚酯用药禁忌（如严重心血管疾病、肝肾功能损害、活动性感染）；
3. 对注射用糖皮质激素不耐受或患有糖皮质激素禁忌症的受试者；
4. 有恶性肿瘤病史，包括实体瘤、血液肿瘤、原位癌，但是在筛选访视前至少 12 个月已切除且治愈的基底细胞癌或皮肤鳞状细胞癌、宫颈不典型增生或 Ⅰ 级原位宫颈癌的受试者可以入组；
5. 有严重输液反应史、鼠蛋白过敏史或抗体过敏史，或相关药物过敏史；
6. 患者既往病史或现病史中有原发性或继发性免疫缺陷，包括人类免疫缺陷病毒（HIV）感染史和HIV检测结果阳性患者；
7. 存在严重的控制不佳的伴随疾病，例如（但不限于）神经系统、肾、肝、内分泌或胃肠道疾病，糖尿病或高血压，并且经研究者判断可能会妨碍受试者加入本研究；
8. 患有任何活动性感染疾病（甲床真菌感染除外），或筛选访视前4周内发生任何需要住院或静脉抗感染治疗的重大感染；或筛选访视前 2 周内接受口服抗感染药治疗的受试者；
9. 实验室检查：天门冬氨酸氨基转移酶（AST）或丙氨酸氨基转移酶（ALT）>2 倍正常范围上限；或血红蛋白 < 80 g/L；或绝对中性粒细胞计数 < 1.5x10^9/L；或血小板计数 < 75x10^9/L。（筛选前 2 周内不允许接受任何医学支持治疗，如：各种升白药、治疗贫血药物、护肝降酶药物、输血等等）；
10. 怀孕或者哺乳期女性受试者，或计划在研究期间或末次给药后12个月内怀孕或哺乳的受试者；
11. 筛选访视前6月内使用过利妥昔单抗等生物制剂；
12. 在筛选访视前12周内接受活疫苗/减毒疫苗的受试者或已知将在24周治疗评估期间会接受活疫苗/减毒疫苗的受试者；
13. 入选本研究前 1 个月内使用其它研究药物或者尚处于其它研究药物的 5 个半衰期内（以时间长者为准）；
14. 研究者认为患者存在不适合参加本研究的疾病或症状，研究药物可能会损害患者健康或者会影响不良事件的判断。Exclusion criteria：
1. Age <18 or >75 years at the time of screening.
2. Known contraindications to rituximab or mycophenolate mofetil (MMF), including but not limited to severe cardiovascular disease, hepatic or renal impairment, or active infections.
3. Intolerance or contraindications to injectable glucocorticoids.
4. History of malignancy, including solid tumors, hematologic malignancies, or carcinoma in situ. (Exception: Subjects with basal cell carcinoma, cutaneous squamous cell carcinoma, cervical dysplasia, or Grade I cervical carcinoma in situ that was surgically excised and deemed cured at least 12 months prior to the screening visit are eligible).
5. History of severe infusion-related reactions, hypersensitivity to murine proteins, monoclonal antibodies, or other relevant drug allergies.
6. Medical history or current diagnosis of primary or secondary immunodeficiency, including a history of Human Immunodeficiency Virus (HIV) infection or a positive HIV test result.
7. Presence of severe, uncontrolled concomitant diseases—including but not limited to neurological, renal, hepatic, endocrine, or gastrointestinal disorders, diabetes, or hypertension—which, in the investigator’s judgment, may preclude participation in the study.
8. Any active infection (excluding onychomycosis); or a history of major infection requiring hospitalization or intravenous (IV) anti-infective therapy within 4 weeks prior to screening; or receipt of oral anti-infective therapy within 2 weeks prior to screening.
9. Laboratory abnormalities at screening: Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 2 $\times$ Upper Limit of Normal (ULN); Hemoglobin < 80 g/L; Absolute Neutrophil Count (ANC) < 1.5 $\times$ 10^9/L; or Platelet count < 75 $\times$ 10^9/L. (Medical supportive therapies, such as colony-stimulating factors, anti-anemic agents, hepatoprotective/enzyme-lowering drugs, or blood transfusions, are prohibited within 2 weeks prior to screening).
10. Female subjects who are pregnant or breastfeeding, or who plan to become pregnant or breastfeed during the study or within 12 months after the final dose.
11. Prior use of biologics, including rituximab, within 6 months prior to the screening visit.
12. Receipt of live or live-attenuated vaccines within 12 weeks prior to screening, or planned vaccination with live/live-attenuated vaccines during the 24-week treatment and assessment period.
13. Participation in another clinical trial involving an investigational product within 1 month prior to enrollment, or within 5 half-lives of the investigational drug, whichever is longer.
14. Any other medical condition or symptom that, in the opinion of the investigator, makes the patient unsuitable for the study, poses a risk to patient safety, or interferes with the assessment of adverse events (AEs).研究实施时间：
Study execute time：
从
From
2026-03-03 00:00:00至
To
2029-03-01 00:00:00
征募观察对象时间：
Recruiting time：
从
From
2026-04-01 00:00:00
至
To
2027-10-31 00:00:00干预措施：
Interventions：
组别：
利妥昔单抗 100mg 组 (低剂量组)
样本量：
40
Group：
Rituximab 100mg Group (Low-dose Group)
Sample size：
干预措施：
利妥昔单抗 (汉利康) 100mg 静脉输注，第 0 周、2 周、6 月、12 月、18 月各 1 次（共 5 次，总剂量 500mg）；联合系统性糖皮质激素（泼尼松 1mg/kg/d 或 1.5mg/kg/d）及复方磺胺甲噁唑片预防感染
干预措施代码：
Intervention：
Rituximab (Hanli Kang) 100mg intravenous infusion once at week 0, week 2, month 6, month 12, and month 18 (total 5 times, total dose 500mg); combined with systemic corticosteroids (prednisone 1mg/kg/d or 1.5mg/kg/d) and compound sulfamethoxazole tablets for infection prevention
Intervention code：
组别：
利妥昔单抗 500mg 组 (标准剂量组)
样本量：
40
Group：
Rituximab 500mg Group (Standard-dose Group)
Sample size：
干预措施：
利妥昔单抗 (汉利康) 500mg 静脉输注，第 0 周、2 周、12 月、18 月各 1 次（共 4 次，总剂量 2000mg）；联合系统性糖皮质激素（泼尼松 1mg/kg/d 或 1.5mg/kg/d）及复方磺胺甲噁唑片预防感染
干预措施代码：
Intervention：
Rituximab (Hanli Kang) 500mg intravenous infusion once at week 0, week 2, month 12, and month 18 (total 4 times, total dose 2000mg); combined with systemic corticosteroids (prednisone 1mg/kg/d or 1.5mg/kg/d) and compound sulfamethoxazole tablets for infection prevention
Intervention code：
组别：
对照组
样本量：
40
Group：
Control Group
Sample size：
干预措施：
口服吗替麦考酚酯 1g bid；联合系统性糖皮质激素（泼尼松 1mg/kg/d 或 1.5mg/kg/d）及复方磺胺甲噁唑片预防感染；禁止使用其他免疫抑制剂
干预措施代码：
Intervention：
Oral mycophenolate mofetil 1g twice daily; combined with systemic corticosteroids (prednisone 1mg/kg/d or 1.5mg/kg/d) and compound sulfamethoxazole tablets for infection prevention; other immunosuppressants prohibited
Intervention code：研究实施地点：
Countries of recruitment and research settings：
国家：
中国
省(直辖市)：
山东
市(区县)：
Country：
China
Province：
Shandong
City：
单位(医院)：
山东第一医科大学附属皮肤病医院
单位级别：
三级甲等
Institution
hospital：
Affiliated Dermatology Hospital of Shandong First Medical University
Level of the institution：
Tertiary A
国家：
中国
省(直辖市)：
上海
市(区县)：
Country：
China
Province：
Shanghai
City：
单位(医院)：
上海交通大学医学院附属瑞金医院
单位级别：
三级甲等
Institution
hospital：
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Level of the institution：
Tertiary A
国家：
中国
省(直辖市)：
江苏
市(区县)：
Country：
China
Province：
Jiangsu
City：
单位(医院)：
中国医学科学院皮肤病医院（中国医学科学院皮肤病研究所）
单位级别：
三级甲等
Institution
hospital：
Chinese Academy of Medical Sciences Institute of Dermatology (Dermatology Hospital)
Level of the institution：
Tertiary A
国家：
中国
省(直辖市)：
四川
市(区县)：
Country：
China
Province：
Sichuan
City：
单位(医院)：
四川大学华西医院
单位级别：
三级甲等
Institution
hospital：
West China Hospital, Sichuan University
Level of the institution：
Tertiary A测量指标：
Outcomes：
指标中文名：
持续完全缓解的患者比例及所需时间
指标类型：
主要指标
Outcome：
Proportion of subjects and the time to onset achieving sustained Complete Remission
Type：
Primary indicator
测量时间点：
52周
测量方法：
评估52周内实现持续完全缓解（停用激素、PDAI为0，且连续16周内无新发皮损，原有皮损也未加重）的患者比例，和所需天数
Measure time point of outcome：
52 weeks
Measure method：
To evaluate the proportion of subjects achieving sustained Complete Remission (defined as a Pemphigus Disease Area Index [PDAI] score of 0, successful discontinuation of corticosteroids, and no new or worsening lesions for at least 16 consecutive weeks) within 52 weeks, and the time to achievement (days).
指标中文名：
抗 Dsg1/3 抗体转阴比例及所需时间
指标类型：
次要指标
Outcome：
Proportion of subjects achieving anti-Dsg1/3 antibody seroconversion (to negative) and the time to seroconversion.
Type：
Secondary indicator
测量时间点：
52 周、104 周
测量方法：
评估52周、104周抗 Dsg1/3 抗体转阴比例及所需时间
Measure time point of outcome：
52 and 104 weeks
Measure method：
To evaluate the proportion of subjects achieving anti-Dsg1/3 antibody seroconversion (to negative) and the time to seroconversion through Week 52 and Week 104.
指标中文名：
复发比例及复发时间
指标类型：
次要指标
Outcome：
Proportion of subjects with disease relapse and the time to relapse.
Type：
Secondary indicator
测量时间点：
52 周、104 周
测量方法：
评估52周、104周复发比例及复发时间
Measure time point of outcome：
52 and 104 weeks
Measure method：
To evaluate the proportion of subjects with disease relapse and the time to relapse through Week 52 and Week 104.
指标中文名：
糖皮质激素最小维持量的患者比例及所需时间
指标类型：
次要指标
Outcome：
Proportion of subjects reaching the minimal maintenance dose of glucocorticoids and the time to achievement.
Type：
Secondary indicator
测量时间点：
52 周、104 周
测量方法：
评估52周、104周达到糖皮质激素最小维持量的患者比例及所需时间。
Measure time point of outcome：
52 and 104 weeks
Measure method：
To evaluate the proportion of subjects reaching the minimal maintenance dose of glucocorticoids and the time to achievement through Week 52 and Week 104.
指标中文名：
糖皮质激素累积剂量（泼尼松相当量）
指标类型：
次要指标
Outcome：
Cumulative Dose of Glucocorticoids (Prednisone Equivalent)
Type：
Secondary indicator
测量时间点：
52 周、104 周
测量方法：
评估52周、104周糖皮质激素累积剂量（泼尼松相当量）
Measure time point of outcome：
52 and 104 weeks
Measure method：
To evaluate the cumulative dose of glucocorticoids (prednisone equivalent) through Week 52 and Week 104.
指标中文名：
达到持续完全缓解的患者比例及所需时间（天）
指标类型：
次要指标
Outcome：
Proportion of subjects and the time to onset (days) achieving sustained Complete Remission
Type：
Secondary indicator
测量时间点：
104周
测量方法：
评估104周内实现持续完全缓解（停用激素、PDAI为0，且连续16周内无新发皮损，原有皮损也未加重）的患者比例，和所需天数
Measure time point of outcome：
104 weeks
Measure method：
To evaluate the proportion of subjects achieving sustained Complete Remission (defined as a Pemphigus Disease Area Index [PDAI] score of 0, successful discontinuation of corticosteroids, and no new or worsening lesions for at least 16 consecutive weeks) within 104 weeks, and the time to achievement (days).
指标中文名：
安全性指标（包括：不良事件/严重不良事件的类型、发生率等）
指标类型：
副作用指标
Outcome：
Safety indicators (including: types of adverse events/serious adverse events, incidence rates, etc.)
Type：
Adverse
events
测量时间点：
测量方法：
Measure time point of outcome：
Measure method：采集人体标本：
Collecting sample(s)
from participants：
标本中文名：
血液
组织：
Sample Name：
Blood
Tissue：
人体标本去向
使用后保存
说明
Fate of sample：
Preservation
after use
Note：征募研究对象情况：
Recruiting status：
尚未开始
Not yet
recruiting
年龄范围：
Participant age：
最小
Min age
18
岁
years
最大
Max age
75
岁
years性别：
男女均可
Gender：
Both随机方法（请说明由何人用什么方法产生随机序列）：
本研究采用随机、平行对照设计，将符合入选资格并签署知情同意书的受试者按照 1:1:1 的比例随机分配至 3 个治疗组。本研究采用中央随机化系统对受试者进行随机分组，随机化方法为“动态随机”，无分层因素。在随机入组受试者过程中，优先保证两个分组的受试者数量平衡。在此前提下，尽量保证每个试验机构中的两个分组的受试者数量平衡。研究者或合格的指定人员通过各自的密码进入交互式应答系统（IWRS），分配给受试者随机号，同时也通过 IWRS 获得受试者相应的需接受的研究药物编号Randomization Procedure (please state who
generates the
random number sequence and by what method)：
This study adopted a randomized, parallel controlled design. Subjects who met the inclusion criteria and signed the informed consent form were randomly assigned to three treatment groups in a ratio of 1:1:1. In this study, the subjects were randomly grouped using a central randomization system. The randomization method was "dynamic randomization", with no stratification factors. During the process of randomly enrolling subjects, priority should be given to ensuring a balanced number of subjects in the two groups. Under this premise, efforts should be made to ensure that the number of subjects in the two groups of each experimental institution is balanced as much as possible. Researchers or qualified designated personnel enter the Interactive Response System (IWRS) through their respective passwords, assign random numbers to the subjects, and also obtain the corresponding drug numbers that the subjects need to receive through IWRS是否公开试验完成后的统计结果:
Calculated Results after the Study Completed public access:
不公开/Private盲法：
开放标签Blinding：
Open-label study是否共享原始数据：
IPD sharing
是Yes共享原始数据的方式（说明：请填入公开原始数据日期和方式，如采用网络平台，需填该网络平台名称和网址）：
本试验数据将在主要研究结果发表后6个月内通过ResMan网站共享。共享内容包括去标识化的IPD、研究方案和统计分析报告。数据将通过安全平台访问，严禁用于商业用途或患者重新识别。The way of sharing IPD”(include metadata and
protocol,
If use web-based public database, please provide
the
url)：
The trial data will be shared via the ResMan website within 6 months after the publication of the primary study results. The shared data will include de-identified IPD (Individual Participant Data), the study protocol, and the statistical analysis report (CSR). Access to the data will be provided through a secure platform, and commercial use or re-identification of patients is strictly prohibited.数据采集和管理（说明：数据采集和管理由两部分组成，一为病例记录表(Case
Record Form, CRF)，二为电子采集和管理系统(Electronic Data
Capture, EDC)，如ResMan即为一种基于互联网的EDC：
本研究的采集将使用专门设计的病例收集表，之后录入山东第一医科大学附属皮肤病医院疱病患者信息管理系统内进行统一保存和管理。Data collection and Management (A
standard data collection and management system
include a CRF and an electronic data capture：
Data will be collected using specially designed case collection forms, which will subsequently be entered into the Pemphigus Patient Information Management System at the Hospital for Skin Diseases, Shandong First Medical University for standardized storage and management.数据与安全监察委员会：
Data and Safety Monitoring Committee：
有/Yes注册人：
Name of Registration：
2026-03-17 10:27:24
2026-03-12
索引号
11330324MB1770496T/2025-1010398150
主题分类
卫生
组配分类
医院
发布机构
县卫生健康局
成文日期
2026-03-12
公开方式
主动公开
永嘉县人民医院药品价目表药品编号药品名称药品规格单位生产厂家零售价格批准文号药品来源省目录ID0000011(集)注射用青霉素钠80万u支山东鲁抗医药股份有限公司0.45H37020079基药国家1126850000036注射用苄星青霉素120万u支华北制药股份有限公司29.8H20044727基药国家1007780010002(集)注射用头孢唑林钠(凯复卓)1g支广东金城金泰制药有限公司14.5H20204005基药国家1688080010082(集)注射用头孢呋辛钠(惠迪森)1.5g支浙江惠迪森药业有限公司8.98H20084091基药国家171620001014(罗氏芬)注射用头孢曲松钠1g支深圳华润九新药业有限公司34.8H10983036基药国家1010140010141(集)(立健松)注射用头孢曲松钠1.0g支深圳立健药业有限公司2.66H20058023基药国家1418860010164注射用头孢他啶阿维巴坦钠/氯化钠注射液(合益泰)2.5g/100ml:0.9g袋湖南科伦制药有限公司326国药准字H20234417非基药2067800010165(集)注射用头孢他啶(泰司汀)1.0g瓶广东金城金泰制药有限公司7.3国药准字H20064886非基药1679300010242(集)注射用拉氧头孢钠0.5g瓶海南海灵化学制药有限公司8.69国药准字H10930103非基药1150230010271(集)注射用头孢美唑钠1g瓶成都倍特药业股份有限公司12.99H20183205非基药171418001028(集)注射用头孢西丁钠(乐皓)1.0g支山东鲁抗医药股份有限公司4.46H20065079非基药1131680020002(集)注射用阿莫西林钠克拉维酸钾0.6g瓶成都倍特药业股份有限公司3.4H20044047基药国家2001430020026(集)2.25注射用哌拉西林钠他唑巴坦钠2.25g瓶瑞阳制药股份有限公司7.3H20073602基药国家2009570020027(集)4.5g注射用哌拉西林钠他唑巴坦钠4.5g瓶瑞阳制药股份有限公司12.41H20073604基药国家200984002004(舒普深1.5)注射用头孢哌酮钠舒巴坦钠1.5g支辉瑞制药有限公司53.38H20020597非基药1019340020043(集)(安士杰)注射用头孢哌酮钠舒巴坦钠1g瓶齐鲁安替制药有限公司3.3H20043200非基药114340002100注射用亚胺培南西司他丁(泰能)1g(0.5g/0.5g)支杭州默沙东制药有限公司125.92HJ20181008，HJ20181007非基药1460490021021(集)注射用美罗培南0.5g瓶山东罗欣药业集团股份有限公司13.61H20163392非基药162970002103注射用厄他培南(怡万之)1g瓶杭州默沙东制药有限公司分包装289.25J20150127非基药1525780030061(集)硫酸阿米卡星注射液(遂成)2ml:0.2g支遂成药业股份有限公司0.69国药准字H41021170非基药201993003007硫酸异帕米星注射液0.2g:2ml支浙江海正药业股份有限公司42.18H20046001非基药154588003008硫酸异帕米星注射液0.4g:4ml支浙江海正药业股份有限公司70.69H20046000非基药1442730040001注射用乳糖酸红霉素（自费）0.25g瓶美罗药业股份有限公司9.5H21021678非基药1035560040079(集)注射用阿奇霉素(巴珠)0.5g瓶海南倍特药业有限公司9.17H20067075非基药115897004008(希舒美)注射用阿奇霉素0.5g瓶晖致制药(大连)有限公司63.19HJ20140685，HJ20130831,HJ20130830非基药1279140051011注射用万古霉素(来可信)0.5g支浙江医药新昌制药厂70.13H20033366非基药1042080051044(集)克林霉素磷酸酯注射液0.3g:2ml支成都天台山制药有限公司0.89H20058631非基药1261450051053(集)300ml利奈唑胺葡萄糖注射液0.6g:300ml袋江苏正大丰海制药公司29.4国药准字H20183528非基药1654970060053(可乐必妥针)左氧氟沙星氯化钠注射液0.5g:100ml袋北京吉洛华制药有限公司84.06H20020636非基药1355230060055(集)左氧氟沙星氯化钠注射液(来立信)0.5g:100ml袋浙江医药股份有限公司新昌制药厂5.99H20213510非基药1734740060056(集)盐酸莫西沙星氯化钠注射液250ml:0.4g:2.0g瓶四川科伦药业股份有限公司14.4国药准字H20193110基药国家165616007001异烟肼注射液0.1:2ml支天津金耀药业有限公司4.85H12020970基药国家1257470080011(大扶康)氟康唑氯化钠注射液0.2g:100ml瓶法国PFIZERPGM157.38H20181194基药国家1475360080012(集)氟康唑氯化钠注射液0.2g:100ml瓶四川科伦药业股份有限公司21.15H20055572基药国家173387008007注射用伏立康唑(威凡)0.2g支爱尔兰PfizerIreland PharmaceuticalsLtd.651.32H20130531非基药1322650080072(集)注射用伏立康唑(倍安特)0.2g瓶海南倍特药业有限公司69国药准字H20223180非基药1755000082015(集)甲硝唑氯化钠注射液0.5g:100ml袋杭州民生药业股份有限公司5.07H20067634基药国家1361160090011(集)注射用更昔洛韦(普更新)0.25g支武汉普生制药有限公司12.2H20045077基药国家132562010009(集)胞磷胆碱钠注射液(苏布林)4ml:0.5g支石家庄四药有限公司1.69H20233684非基药204256010018吡拉西坦氯化钠注射液100ml:20g瓶山东威高药业有限公司33.82H20073420非基药1170680100182(集)吡拉西坦注射液5ml:1g支湖北津药药业股份有限公司2.63H20093517非基药150815010019丁苯酞氯化钠注射液100ml:25mg:0.9g瓶石药集团恩必普药业有限公司102.16国药准字H20100041非基药1197960100231(集)醒脑静注射液(人工麝香)10ml支无锡济煜山禾药业股份有限公司19.64Z32020563非基药145733010028参芪扶正注射液250ml瓶丽珠集团利民制药厂106.84Z19990065非基药1058900100281(集)参麦注射液(正大青春宝)50ml瓶正大青春宝药业有限公司24.28国药准字Z33020019基药国家106306011000曲马多注射液0.1:2ml支德国格兰泰制药 10.17H20140813非基药011005布托啡诺注射液(诺扬)1mg:1ml支江苏恒瑞医药股份公司36.52H20020454非基药011006地佐辛注射液5mg:1ml支扬子江药业集团有限公司148H20080329非基药0120072(集)布洛芬注射液4ml:0.4g支成都倍特药业股份有限公司7.9H20203473非基药171539012008注射用氯诺昔康8mg支浙江震元制药有限公司11.29H20043685非基药130996014004氟哌啶醇注射液1ml:5mg支湖南洞庭药业股份有限公司15H43020555基药国家1201500140041癸酸氟哌啶醇注射液(哈力多)1ml:50mg支泰国Atlantic Laboratories Corporation, Ltd.29.13国药准字HJ20160625非基药147477014005棕榈酸帕利哌酮注射液(醒必达)1.0ml:100mg支齐鲁制药有限公司1085国药准字H20234233基药国家20607301400637.5mg注射用利培酮微球(Ⅱ)(瑞可妥)37.5mg支山东绿叶制药有限公司924.77H20210002非基药174202014006125mg注射用利培酮微球(Ⅱ)(瑞可妥)25mg支山东绿叶制药有限公司678国药准字H20210001非基药1720960140062注射用阿立哌唑(安律凡)0.4g支浙江大冢制药有限公司892.16国药准字HJ20230055非基药207908015000地西泮注射液10mg:2ml支上海旭东海普药业有限公司9.8H31021864基药国家015002注射用苯巴比妥钠0.1g支福建闽东力捷迅药业有限公司68.8H20057384基药国家0151013(集)天麻素注射液2ml:0.2g支华润双鹤利民药业(济南)有限公司0.75H20059653非基药146680020002吸入用七氟烷(凯特力)1ml*120瓶上海恒瑞医药有限公司661.99H20213735基药国家203895020003咪达唑仑注射液2mg:2ml支宜昌人福药业有限公司7.3H20067040非基药0200041咪达唑仑注射液(力月西)50mg:10ml支江苏恩华药业股份有限公司86.05H20143222非基药0200052(集)盐酸右美托咪定注射液(辰皎)0.2mg:2ml支辰欣药业股份有限公司5.06H20130027非基药150789020006盐酸纳布啡注射液(瑞静)20mg:2ml支宜昌人福药业有限公司99.3H20130127非基药0200061盐酸纳布啡注射液(欣苏宁)10mg:1ml支扬子江药业江苏紫龙药业有限公司60H20213459非基药0210001盐酸艾司氯胺酮注射液50mg:2ml支江苏恒瑞医药股份有限公司91.8H20193336非基药0210042(集)依托咪酯乳状注射液(福尔利)10ml:20mg支江苏恩华药业股份有限公司33.58H20020511非基药107966021009丙泊酚乳状注射液(静安)0.2g:20ml支北京费森尢斯卡比医药有限公司14.4HJ20170306基药国家1277170210091(集)丙泊酚乳状注射液(力蒙静)1g:50ml瓶西安力邦制药有限公司16.57H20123318非基药1489350220071(集)盐酸利多卡因注射液0.1g:5ml支湖南科伦制药有限公司2.23H20057816基药国家165806022012(耐乐品)盐酸罗哌卡因注射液75mg:10ml支瑞典ASTRAZENECE A B26.73H20140764基药国家1322250220123(集)盐酸罗哌卡因注射液(卓坦)75mg:10ml支齐鲁制药有限公司4.01H20052716基药国家114120022014注射用盐酸氯普鲁卡因(可谱诺)0.5g支晋城海斯药业有限公司52.25H20020082非基药100737022015阿替卡因肾上腺素注射液(必兰)1.7ml:68mg:17ug支法国碧兰公司PRODUITS DENTAIRES PIERRE ROLLAND6.9进口药品注册证号HJ20140732非基药1473720230042(集)舒更葡糖钠注射液(芬可畅)2ml:200mg支成都苑东生物制药股份有限公司9.33国药准字H20223382非基药1762190230043(集)罗库溴铵注射液50mg:5ml支峨眉山通惠制药有限公司13.38国药准字H20183305基药国家1647310240061(集)苯磺顺阿曲库铵注射液10mg:5ml瓶杭州澳亚生物技术股份有限公司15.36H20213438非基药1734730260001(集)甲硫酸新斯的明注射液0.5mg:1ml支浙江仙琚制药股份有限公司0.78H20057097基药国家1421200260052(集)硫酸阿托品注射液1ml:0.5mg支杭州民生药业股份有限公司0.67H20237033基药国家210152026010消旋山莨菪碱注射液10mg:1ml支杭州民生药业有限公司2.38H33021707基药国家135928026014甲磺酸酚妥拉明注射液10mg:1ml支上海旭东海普药业有限公司7.18H31020589基药国家138271030000去乙酰毛花苷注射液0.4mg:2ml支上海旭东海普药业有限公司37H31021178基药国家1381030300031(新活素)注射用重组人脑利钠肽0.5mg/500U瓶成都诺迪康生物制药有限公司424.98国药准字S20050033非基药1182230300033(集)米力农注射液10mg:10ml支上海旭东海普药业有限公司12.93H20203726非基药171645031001盐酸胺碘酮注射液(可达龙)0.15g:3ml支赛诺菲（杭州）制药有限公司21.5HJ20225004非基药1470980310012(集)盐酸胺碘酮注射液(创新)3ml:150mg支浙江创新生物有限公司5.98H20233179非基药2105080310021(集)盐酸艾司洛尔注射液10ml:0.1g支山东鲁抗医药集团赛特有限责任公司1.58国药准字H20067704基药国家2128340310041盐酸普罗帕酮注射液(自费)70mg:20ml支上海信谊金朱药业有限公司30H31022214非基药210635031005(临)腺苷注射液2ml:6mg支蓬莱诺康药业有限公司197.99H20174051非基药163210032000硝酸甘油注射液5mg:1ml支山西康宝生物制品有限公司11.49H14022197基药国家1089060320011(集)盐酸替罗非班氯化钠注射液(科蓝)100ml:5mg:0.9g瓶石药集团恩必普药业有限公司29.8H20183440非基药1670340320051丹红注射液20ml支山东丹红制药有限公司28.76Z20026866非基药116261033003(集)注射用血栓通(冻干)0.1g支广西梧州制药(集团)有限公司5.68Z20025652基药国家1155530330031(集)注射用血塞通(冻干)0.2g支哈尔滨珍宝制药有限公司7.8Z20026437基药国家1167290330032(集)血塞通注射液2ml:100mg支沈阳神龙药业有限公司1.15国药准字Z21021266非基药214021033006(集)银杏达莫注射液(杏丁)5ml支贵州益佰制药有限公司6.25H52020032非基药114416033007银杏叶提取物注射液5ml:17.5mg支悦康药业集团股份有限公司11.2H20070226非基药1457230340001(集)盐酸肾上腺素注射液1ml:1mg支津药和平(天津)制药有限公司1.28国药准字H12020526基药国家125837034002(集)去氧肾上腺素注射液10mg:1ml支上海禾丰制药有限公司6.87H31021175非基药1443900340042(集)去甲肾上腺素注射液1ml:2mg支津药和平(天津)制药有限公司0.54国药准字H12020621基药国家125831034006(集)盐酸异丙肾上腺素注射液1mg:2ml支上海禾丰制药有限公司30.39H31021344基药国家144393034007(集)重酒石酸间羟胺注射液10mg:1ml支津药和平(天津)制药有限公司1.21H12020620基药国家125826034009盐酸多巴胺注射液20mg20mg:2ml支上海禾丰制药有限公司3.61H31021174基药国家1444290360014(集)依达拉奉注射液(易达生)30mg:20ml支吉林省博大制药股份有限公司3.78H20051992非基药1154350360053(集)(罗迪平)盐酸乌拉地尔注射液5ml:25mg支石家庄四药有限公司1.96H20233626基药国家2041950380001(集)呋塞米注射液20mg:2ml支山东新华制药股份有限公司2.85H37020293基药国家1771170381002(临)20%甘露醇注射液100ml:20g袋湖南科伦制药有限公司1.74国药准字H43020483非基药1085490381031注射用七叶皂苷钠15mg支山东绿叶制药有限公司19.31H20023113非基药136266038203(集)左卡尼汀注射液(可益能)1g:5ml支意大利Sigma-Tau9H20171294非基药132232040001麻黄碱注射液30mg:1ml支东北制药集团公司沈阳第一制药厂4.116H21022412非基药0400034(集)盐酸氨溴索注射液(科伦)15mg:2ml支湖北科伦药业有限公司0.23H20183050非基药1734650400044(集)氨茶碱注射液10ml:0.25g支湖南尔康制药股份有限公司0.97国药准字H43020843非基药2097470400052(集)多索茶碱注射液(仁畅)0.1g:10ml支扬子江药业集团南京海陵药业有限公司3.6H20203304非基药1711640410001盐酸异丙嗪注射液25mg:1ml支上海禾丰制药有限公司1.68H31021490基药国家1443940430011垂体后叶注射液6u:1ml支安徽宏业药业有限公司80H34022977基药国家1115030430023(集)缩宫素注射液(倍特)1ml:10u支成都倍特药业股份有限公司2.35H20233755基药国家2047690430041前列地尔注射液(益康宁)10ug:2ml支本溪恒康制药有限公司58.6H20093175非基药1212900430051乳酸依沙吖啶注射液50mg:2ml支广西河丰药业有限责任公司57.33H45020606基药国家149252044000地塞米松磷酸钠注射液2mg:1ml支湖北津药药业股份有限公司0.22H42020020基药国家1503490440010(集)地塞米松磷酸钠注射液 1ml:5mg支海南倍特药业有限公司0.57H32021561非基药1570830440021醋酸曲安奈德注射液20mg:2ml支浙江仙琚制药股份有限公司2.81H20033524非基药142022044006(得宝松)复方倍他米松注射液2mg:5mg:1ml支杭州默沙东制药有限公司分包装38.53HJ20130187/HJ20130188基药国家1277500440083(集)注射用甲泼尼龙琥珀酸钠(命得生)40mg瓶南光化学制药股份有限公司4.84HC20160039基药国家1299780450021(集)注射用人生长激素(赛增)4.5iu:1.7mg:1ml瓶长春金赛药业股份有限公司32.51S10980101非基药1238540450032(集)(达菲林)注射用醋酸曲普瑞林3.75mg瓶法国 IPSEN PHARMA BIOTECH998.4H20140298非基药1201460450033(达必佳)注射用曲普瑞林3.75mg支德国辉凌制药1179.3进口注册证号HJ20140123非基药1418660450035(集)醋酸曲普瑞林注射液0.1mg:1ml瓶重庆莱美药业有限公司44.05H20223597非基药176654045004黄体酮注射液20mg:1ml支浙江仙琚制药股份有限公司2.59H33020828基药国家1421250450051(集)注射用醋酸亮丙瑞林微球(贝依）3.75mg瓶上海丽珠制药有限公司903.86H20093852非基药1054240450103.6mg醋酸戈舍瑞林缓释植入剂(诺雷得)3.6mg支英国AstraZeneca UK Limited1073.75HJ20160259非基药16612104501110.8mg醋酸戈舍瑞林缓释植入剂(诺雷得)10.8mg支英国AstraZeneca UK Limited2489.76国药准字HJ20160244非基药17164004600胰岛素注射液400u:10ml支江苏万邦生化医药有限公司23.82H10890001基药国家1420610460011(集)(诺和灵30R)精蛋白人胰岛素混合注射液(30R)300IU:3ml支诺和诺德(中国)制药有限公司29.56国药准字S20191005基药国家15518104600113(集)(普秀霖30R)精蛋白人胰岛素混合注射液300IU:3ml支甘李药业股份有限公司25.9S20210015基药国家1743860460041(集)(诺和灵50R)精蛋白人胰岛素混合注射液(50R)300IU:3ml支诺和诺德(中国)制药有限公司29.56国药准字S20191006非基药127217046007(集)(优泌乐25)精蛋白锌重组赖脯胰岛素混合注射液300IU:3ml支礼来(苏州)制药有限公司38.42S20237011非基药211298046008(集)(优泌乐50)精蛋白锌重组赖脯胰岛素混合注射液300IU:3ml支礼来(苏州)制药有限公司38.42SJ20171020非基药1308470460101(集)(长秀霖)甘精胰岛素注射液300IU:3ml支甘李药业股份有限公司65.3S20050051基药国家1171560460102(集)(来优时)甘精胰岛素注射液450IU:1.5ml支赛诺菲（北京）制药有限公司89.91国药准字S20237010非基药209799046011(集)(诺和锐特充)门冬胰岛素注射液300IU:3ml支诺和诺德(中国)制药有限公司38.55S20217012非基药1743380460112(集)(锐秀霖)门冬胰岛素注射液300IU:3ml支甘李药业股份有限公司25.9S20200008非基药1727670460121(集)(锐秀霖30)门冬胰岛素30注射液300IU:3ml支甘李药业股份有限公司25.9S20200024非基药172766046013(集)(诺和锐30特充)门冬胰岛素30注射液300IU:3ml支诺和诺德(中国)制药有限公司38.55S20217010非基药1743390460131(集)(锐舒霖50)门冬胰岛素50注射液300IU:3ml支通化东宝药业股份有限公司23.98国药准字S20220031非基药2042630460141(诺和平特充)地特胰岛素注射液300IU:3ml支诺和诺德(中国)制药有限公司82.2S20217014非基药175435046017(集)(速秀霖25R)精蛋白锌重组赖脯胰岛素混合注射液300IU:3ml支甘李药业股份有限公司35.55S20140005非基药1573920460171(集)(速秀霖)赖脯胰岛素注射液300IU:3ml支甘李药业股份有限公司35.55S20063004非基药117180046019度拉糖肽注射液(度易达)1.5mg:0.5ml支德国Vrtter Pharma-Fertigung GmbH Co.KG123.35SJ20190022非基药1655730460193司美格鲁肽注射液(诺和泰)2mg:1.5ml支诺和诺德(中国)制药有限公司分包装421.34SJ20210014非基药1738520460200(诺和佳笔芯)德谷门冬双胰岛素注射液300IU:3ml支诺和诺德(中国)制药有限公司64.36S20227005非基药176242046023(临)(诺和益)德谷胰岛素利拉鲁肽注射液3ml:300u:10.8mg支诺和诺德(中国)制药有限公司217.6SJ20210026非基药174851048001(集)(密盖息)鲑降钙素注射液50iu:1ml支瑞士诺华制药有限公司38.36H20170203非基药132263048002(集)(固通宁)鲑降钙素注射液1ml:50iu:8.3ug支北京双鹭药业股份有限公司3.885国药准字H20020694非基药142740049003地舒单抗注射液(普罗力)60mg:1.0ml(预充式)支美国Amgen Manufacturing Linmited623.53进口注册证号S20200019非基药1711320500001盐酸甲氧氯普胺注射液10mg:2ml支天津金耀药业有限公司1.9H12020967非基药1258930500012(集)盐酸昂丹司琼注射液(枢丹)8mg:4ml支福安药业集团宁波天衡制药有限公司10.3H10960148非基药1380680500022(集)盐酸托烷司琼注射液(民生)5mg:5ml支杭州民生药业股份有限公司1.19H20052664非基药1358380500061(潘妥洛克)注射用泮托拉唑钠40mg支德国Takeda GmbH69.86H20150524非基药1474220500066(集)注射用泮托拉唑钠(泮立苏)40mg支杭州中美华东制药有限公司2.56H19990166非基药1266930500071(集)注射用兰索拉唑(奥维加)30mg支江苏奥赛康药业有限公司4.39H20080336非基药1433820500084(集)注射用奥美拉唑钠(静滴)60mg瓶浙江亚太药业股份有限公司1.35H20123397非基药152140050010(集)(双鹤)间苯三酚注射液4ml:40mg支华润双鹤利民药业(济南)有限公司0.44H20243728非基药213402052007(美能)复方甘草酸苷注射液20ml支卫材(中国)药业有限公司16.08HJ20181051,HJ20181052非基药1295370520072异甘草酸镁注射液(天晴甘美)50mg:10ml支江苏正大天晴药业股份有限公司27.55H20051942非基药1187040520073(集)复方甘草酸苷注射液(甘普洛)20ml支西安远大德天药业股份有限公司1.32H20066563非基药117049052016(集)注射用门冬氨酸鸟氨酸(瑞甘)2.5g支武汉启瑞药业有限公司18.04H20060632非基药1273460520161门冬氨酸鸟氨酸注射液(雅博司)5g:10ml支德国麦氏大药厂41.36进口注册证H20130430非基药1421910520172(集)盐酸精氨酸注射液5g:20ml支上海信谊金朱药业有限公司6.6国药准字H31021692基药国家1342620530003(集)醋酸奥曲肽注射液0.1mg:1ml支海南中和药业股份有限公司8.99H20103209非基药112035054001(思美泰)注射用丁二磺酸腺苷蛋氨酸0.5g支上海雅培制药有限公司49.68HJ20171084,HJ20171069非基药1625270600001维生素K1注射液(自费)10mg:1ml支浙江诚意药业有限公司15.8H33020864基药国家1307450600022(巴曲亭)注射用矛头蝮蛇血凝酶1u支蓬莱诺康药业有限公司36.19H20041419非基药1111110600023(苏灵)注射用尖吻蝮蛇血凝酶1u支北京康辰药业股份有限公司59.15H20080633非基药101711060003酚磺乙胺注射液0.5g:2ml支上海上药第一生化药业有限公司0.867H31021895非基药1324100600051(集)氨甲环酸注射液5ml:0.25g支成都第一药业有限公司2.88H51021961基药国家2100940600112(临)人凝血酶原复合物300IU瓶山东泰邦生物制品有限公司263.7S20140008基药国家162225060021(临)人纤维蛋白原0.5g瓶山东泰邦生物制品有限公司800S20170007基药国家1632290610001(集)肝素钠注射液2ml:12500u支辰欣药业股份有限公司4.34国药准字H20043156基药国家157401061002注射用甲磺酸萘莫司他(扶渡)50mg瓶山东裕欣药业有限公司36.34国药准字H20203509非基药17166806100311(集)低分子量肝素钠注射液(齐征)5000IU:0.4ml支齐鲁制药有限公司7.87H20030429基药国家1184490610032(集)(法安明)达肝素钠注射液5000IU:0.2ml支辉瑞制药有限公司进口分包装（德国Vetter为辉瑞比利时公司生产）28.95HJ20170040,HJ20170041,HJ20170042非基药1628210610036(集)依诺肝素钠注射液4000AXaIU:0.4ml支辰欣药业股份有限公司13.87H20223799基药国家2102690610043注射用尿激酶10万u支南京南大药业有限责任公司135H10920040非基药140048061005注射用阿替普酶(爱通立)50mg支德国勃林格殷格翰制药有限公司3400国药准字SJ20160055非基药1475050610052注射用阿替普酶(爱通立)20mg支德国勃林格殷格翰制药有限公司1685.94国药准字SJ20160054非基药147504061007(明复乐)注射用重组人TNK组织型纤溶酶原激活剂16mg/1.0*10(7次方)IU支石药集团明复乐药业(广州)有限公司3333.03S20150001非基药1634370620008(集)甲钴胺注射液(艾飞利)0.5mg:1ml支石家庄四药有限公司0.98H20066715非基药1643400620042(集)(益比奥预充)人促红素注射液10000IU:1ml支沈阳三生制药有限责任公司53.06S20010001基药国家1037310620043(集)(雪达升预充)人促红素注射液3000IU:1ml支哈药集团生物工程有限公司7.1S20050090基药国家122925062008甲钴胺注射液(弥可保)500ug:1ml支卫材(中国)药业有限公司9.88国药准字H20174048非基药1636530620091(集)蔗糖铁注射液5ml:100mg支山西普德药业有限公司8.5H20057617非基药130589063003羟乙基淀粉氯化钠注(200/0.5盈源)500ml瓶华润双鹤药业股份有限公司74.78H20050886非基药119587063006人血白蛋白注射液(进口)10g:50ml瓶美国杰特贝林生物制品有限公司420S20190035非基药147151064000(惠尔血)人粒细胞刺激因子注射液75ug:0.3ml支协和发酵麒麟（中国）制药有限公司171.36SJ20171033非基药1621700640011(吉粒芬)人粒细胞刺激因子注射液100ug:0.4ml支杭州九源基因工程有限公司45.39S20033004非基药145873070000110％葡萄糖注射液(国)100ml瓶浙江国镜药业有限公司1.33H33022606基药国家128681070002110％葡萄糖注射液(软)250ml瓶杭州民生药业有限公司3.36H33021404基药国家160595070004110％葡萄糖注射液(软)500ml袋杭州民生药业有限公司3.83H33021631基药国家16059607000625%葡萄糖注射液（瑞）500ml袋浙江天瑞药业有限公司2.16H33020670基药国家13265407000725%葡萄糖注射液(辰)250ml瓶辰欣药业股份有限公司1.7H37021756基药国家16065907000735%葡萄糖注射液(国境)100ml袋浙江国镜药业有限公司1.33H33022607基药国家128693070008150％葡萄糖注射液(塑)20ml支中国大冢制药有限公司1.1H20043272基药国家102521070010葡萄糖氯化钠注射液(民)500ml瓶杭州民生药业有限公司3.94H33021964基药国家160536070011葡萄糖氯化钠注射液(民)250ml瓶杭州民生药业有限公司3.46H33022641基药国家16052807001324:1葡萄糖氯化钠注射液(软)100ml袋杭州民生药业有限公司2.96H20023234基药国家13615107001334:1葡萄糖氯化钠注射液(软)250ml袋杭州民生药业有限公司3.48H20045985基药国家1361580700140.9％氯化钠注射液10ml支上海信谊金朱药业有限公司0.25H31021690基药国家13430507001410.9％氯化钠注射液(塑)10ml支中国大冢制药有限公司0.87H20043271基药国家10251107001450.9％氯化钠注射液(直立式)50ml瓶浙江国镜药业有限公司1.33H20056104基药国家12866407001620.9%氯化钠注射液(双阀)100ml袋辰欣药业股份有限公司3.12H20013310基药国家13499407001710.9％氯化钠注射液(瑞)250ml袋浙江天瑞药业有限公司1.78H33022242基药国家13264307002010.9%氯化钠注射液(国镜)500ml瓶浙江国镜药业有限公司1.89H33020482基药国家12866307002020.9％氯化钠注射液(民)1000ml瓶杭州民生药业有限公司7.28H20043304基药国家136118070021浓氯化钠注射液1g:10ml支湖北天圣药业有限公司0.37H42020422基药国家118572070022复方氯化钠注射液500ml瓶浙江济民制药股份有限公司1.23H19983117基药国家1337170700242(集)乳酸钠林格注射液500ml瓶湖南科伦制药有限公司1.94国药准字H20067464基药国家1137290700255％碳酸氢钠注射液10ml支上海现代哈森(商丘)药业有限公司3H20043781基药国家14220907002515%碳酸氢钠注射液(五官科)10ml:0.5g支中国大冢制药有限公司12H20183434基药国家16672107002615％碳酸氢钠注射液(回音必)250ml:12.5g瓶回音必集团（江西）东亚制药有限公司5.29H36020283基药国家1409060700272(集)15％氯化钾注射液(塑)10ml:1.5g支湖南科伦制药有限公司0.28H20249307基药国家2120330700281(集)葡萄糖酸钙注射液10ml:1g支海南倍特药业有限公司0.89H32021757基药国家1571110700291(集)50%硫酸镁注射液10ml:5g支扬州中宝药业股份有限公司2.35国药准字H20237030非基药2079050700311灭菌注射用水(自费)5ml支遂成药业股份有限公司0.22H41024240非基药2017870700321灭菌注射用水(自费)500ml瓶石家庄四药股份有限公司3.2H20046572非基药1223640700421(集)腹膜透析液(1.5%)2000ml(1.5%)袋华仁药业股份有限公司14.83H20113088基药国家2108840700422(集)腹膜透析液(2.5%)2000ml(2.5%)袋华仁药业股份有限公司14.83H20113091基药国家2108880700423(集)低钙腹膜透析液(1.5%)2000ml(1.5%)袋华仁药业股份有限公司14.83H20183308基药国家2090190700424(集)低钙腹膜透析液(2.5%)2000ml(2.5%)袋华仁药业股份有限公司14.83H20183310基药国家209216070046(集)血液滤过置换基础液4000ml袋华仁药业股份有限公司14.83非基药1651580710021复方氨基酸注射液(20AA)500ml:50g瓶辰欣药业股份有限公司66.23H20064829非基药134335071004(乐凡命)复方氨基酸注射液(18AA-Ⅱ)8.5%:250ml瓶费森尤斯卡比华瑞制药有限公司21.06H10980029非基药1343240710041(集)复方氨基酸注射液(18AA-Ⅱ)250ml:21.25g(8.5%)瓶辰欣药业股份有限公司9.8国药准字H20057116非基药134333071007脂肪乳注射液(英脱利匹特)10%:500ml瓶费森尤斯卡比华瑞制药有限公司40.44H19993195非基药1343840710071(集)结构脂肪乳注射液(C6-24)(力文)250ml:20%袋费森尤斯卡华瑞制药有限公司（Fresenius Kabi AB)196.97J20160046非基药1463500710092(Ⅱ)注射用脂溶性维生素(Ⅱ)1支支华北制药股份有限公司31.92国药准字H20060574非基药1007100710131(集)果糖注射液(韦贝仙)250ml:25g瓶四川科伦药业股份有限公司6.1H20052177非基药1088970710153(集)(多特)脂肪乳氨基酸(17)葡萄糖(11%)注射液1440ml袋四川科伦药业股份有限公司59.5国药准字H20173381基药国家163027072000维生素Ｂ1注射液0.1:2ml支天津金耀药业有限公司0.43H12020613基药国家1259770720021(集)维生素B6注射液50mg:1ml支常州制药厂有限公司0.18H32021704基药国家103168072008(集)帕立骨化醇注射液1ml:5ug支山西威奇达光明制药有限公司15国药准字H20193419非基药1667370720091(集)维生素C注射液1g:5ml支常州制药厂有限公司0.34H32022713基药国家1031820730072(集)玻璃酸钠注射液(腾立克)2.5ml:25mg支上海昊海生物科技股份有限公司39.98H20174089非基药1748870740033(集)注射用环磷腺苷葡胺(凯缌）60mg瓶无锡凯夫制药有限公司20.8H20060650非基药1433960740034聚桂醇注射液10ml:100mg瓶陕西天宇制药有限公司424.43H20080445非基药144829074004(集)破伤风抗毒素1500iu支江西生物制品研究所15.09S10970021基药国家1401540740104(集)骨瓜提取物注射液5ml:25mg支哈尔滨圣泰制药有限公司17.93H23023507非基药11125507401211注射用鼠神经生长因子(金路捷)20ug(≥9000AU)支武汉海特生物制药股份有限公司131.4S20060051非基药1071830740123脑苷肌肽注射液2ml支吉林四环制药有限公司56.1H22025046非基药1287850740125(集)硫辛酸注射液0.3g:12ml支亚宝药业集团股份有限公司6.85H20203417非基药1713450800002注射用环磷酰胺(安道生)0.2g支德国Baxter Oncology GmbH24.15进口注册证号H20160467基药国家1280960810002甲氨蝶呤注射液50mg:2ml支澳大利亚Pfizer(Perth)Pty Limited97进口药品注册证号H20140205非基药165131081001氟尿嘧啶注射液0.25:10ml支天津金耀药业有限公司2.53H12020959基药国家125971082005注射用表柔比星10mg支辉瑞制药（无锡）有限公司122H20000496非基药1441260830044(集)多西他赛注射液(天伦)20mg:0.5ml支扬子江药业集团有限公司30H20093850非基药1018860830071康艾注射液5ml支长白山制药股份有限公司11.73Z20026868非基药126837084004注射用奥沙利铂(乐沙定)50mg支赛诺菲（杭州）制药有限公司1760HJ20171054基药国家1471030840042(集)奥沙利铂注射液50mg:10ml瓶四川汇宇制药股份有限公司76.6H20213060非基药1724000840053(集)注射用唑来膦酸浓溶液(苏奇)4mg:5ml支扬子江药业四川海蓉药业有限公司36H20123153非基药101840087003卡介菌多糖核酸注射液0.35mg:1ml支陕西医药控股集团生物制品有限公司5.08S20043032非基药1422600870031卡介菌纯蛋白衍生物(BCG-PPD)50IU:1ml支成都生物制品有限公司45.6S20010052非基药1078270870032(临)结核菌素纯蛋白衍生物(TB-PPD)注射液50IU:1ml支北京祥瑞生物制品股份有限公司132S10960016基药国家1560740870091(集)注射用胸腺法新(欣菲乐)1.6mg支扬子江药业广州海瑞制药15.5H20193180非基药173110087010注射用胸腺法新(日达仙)1.6mg支意大利Patheon Italia S.P.A450HJ20171177非基药141573087012破伤风人免疫球蛋白250IU支山东泰邦生物制品有限公司285S20053090基药国家127888087013狂犬病人免疫球蛋白200IU支广东双林生物制药有限公司139.99S20063013非基药165593087014(Vero细胞)冻干人用狂犬病疫苗2.5IU(0.5ml)支辽宁成大生物股份有限公司75S20043090非基药087015(人二倍体细胞)冻干人用狂犬病疫苗2.5IU(1.0ml)瓶成都康华生物制品股份有限公司300S20120007非基药0870151静注人免疫球蛋白(PH4)2.5g支华兰生物工程重庆有限公司556S20113011非基药1481570870153吸附破伤风疫苗(预灌式)40iu/0.5ml支成都欧林生物科技股份有限公司180国药准字S20237005非基药087016(可善挺150)司库奇尤单抗注射液1ml:150mg支瑞士Novartis Pharma Stein AG778.65进口药品注册证号S20190023非基药3004170900002(集)注射用谷胱甘肽(罗普司宁)0.6g瓶山东裕欣药业有限公司4.7H20193128非基药165959091001碘解磷定注射液0.5g:20ml支开封制药（集团）有限公司91H41022180基药国家120614091005盐酸戊乙奎醚注射液(长托宁)1mg:1ml支锦州奥鸿药业有限责任公司40H20020606基药国家126976092000亚甲蓝注射液20mg:2ml支济川药业集团有限公司12.18H32024827基药国家134267092001注射用硫代硫酸钠0.64g支上海新亚药业有限公司54H31020534基药国家1340120940014(集)盐酸纳美芬注射液（抒钠）1ml:0.1mg支辽宁海思科制药有限公司6.1H20080652非基药1065380940015(集)盐酸纳洛酮注射液(度宁)2ml:2mg支山东新华制药股份有限公司1.3国药准字H20055763基药国家213408094003(集)氟马西尼注射液(人福)5ml:0.5mg支宜昌人福药业有限责任公司10.74H20113191基药国家11234609600321(集)碘海醇注射液35g35g:100ml瓶通用电气药业(上海)79.42H20000599非基药12707109600322(临)罂粟乙碘油注射液(优力影)10ml(含(I)480mg/ml)支江苏恒瑞医药股份有限公司894.99国药准字H20163348非基药1626710960033注射用六氟化硫微泡(声诺维)59mg支上海博莱科信谊药业有限责任公司512.27HJ20171213非基药1771520960038(集)碘帕醇注射液(典比乐)100ml:37g(I)瓶上海博莱科信谊药业有限责任公司119.28H20053388非基药144332096006钆布醇注射液(优力显)7.5ml7.5ml:4.5354g瓶江苏恒瑞医药股份有限公司144.37H20223154非基药175724098000盐酸吗啡注射液10mg:1ml支东北制药集团公司沈阳第一制药厂3.72H21022436基药国家098001盐酸哌替啶注射液100mg:2ml支东北制药集团公司沈阳第一制药厂2.95H21022413基药国家098002盐酸哌替啶注射液50mg:1ml支青海制药厂有限公司1.73H63020022基药国家098003枸橼酸芬太尼注射液0.1mg:2ml支宜昌人福药业有限公司4.2H42022076基药国家0980041枸橼酸舒芬太尼注射液(国)50ug:1ml支宜昌人福药业有限公司51.74H20054171非基药098006注射用盐酸瑞芬太尼(瑞捷)1mg支宜昌人福药业有限公司89.9H20030197基药国家098010硫酸吗啡缓释片(美施康定)30mg*10盒萌蒂（中国）制药有限公司96.45J20140060基药国家0980101硫酸吗啡缓释片(美施康定)10mg*10盒萌蒂（中国）制药有限公司49.21H10980263基药国家098012盐酸吗啡片10mg*20盒东北制药集团公司沈阳第一制药厂26.7H20063220基药国家098013盐酸羟考酮缓释片(奥施康定)40mg*10盒萌蒂（中国）制药有限公司317.56J20140127非基药0980141盐酸羟考酮缓释片(奥施康定)10mg*30盒萌蒂（中国）制药有限公司238.26J20140125非基药098016芬太尼透皮贴剂(多瑞吉)4.2mg贴西安扬森制药有限公司77.42HJ20150592非基药1000012阿莫西林胶囊(阿莫灵)0.5g*20盒澳美制药厂12.03进口注册证号HC20160036非基药1323401000014(集)阿莫西林胶囊(石药)0.25g*30盒石药集团中诺药业(石家庄)有限公4.14H13023964非基药1650671000052(巨泰)阿莫西林克拉维酸钾胶囊(4:1)156.25mg*24盒浙江巨泰药业有限公司21.03H20030190非基药139084101005(集)头孢丙烯片0.25g*12盒南京亿华药业有限公司8.16H20041960非基药1110181010062(集)头孢呋辛酯片(达力新)0.25g*12盒国药集团致君（深圳）制药有限公司5.1H20000400基药国家1236321010071(集)头孢克洛胶囊0.25g*12盒苏州中化药品工业有限公司7.3国药准字H20033599非基药1659951010112(集)头孢地尼胶囊0.1g*24盒石家庄四药股份有限公司12.2国药准字H20203289非基药1710561020015盐酸多西环素肠溶胶囊(永喜)0.1g*20盒德全药品(江苏)股份有限公司26.71国药准字H20030627非基药1370201020062(集)克拉霉素片0.25g*8盒浙江贝得药业有限公司3.75国药准字H20083281基药国家1690171020072(集)阿奇霉素片(维宏)0.25g*6盒石药集团欧意药业有限公司4.98国药准字H10980218基药国家1103301040062(集)左氧氟沙星片0.5g*7片*4板盒长春海悦药业股份有限公司14.48H20203307非基药1717961040063(可乐必妥片)左氧氟沙星片0.5g*4盒北京吉洛华制药有限公司33.12H20040091非基药1356651040071(集)盐酸莫西沙星片(言宁)0.4g*6盒重庆华邦制药有限公司17.69国药准字H20193406基药国家167009105001柳氮磺吡啶肠溶片0.25g*60片盒上海信谊天平药业有限公司19H31020557基药国家143774105004(集)盐酸克林霉素胶囊(珍宝岛)0.15g*12盒哈尔滨珍宝制药有限公司1.44H20003860基药国家166574105102呋喃妥因肠溶片50mg*100片瓶天津力生制药股份有限公司7.48H12020164基药国家111484105103(集)复方磺胺甲噁唑片0.48g*100瓶宜昌人福药业有限责任公司24.65H42022114基药国家112095105104(集)利奈唑胺片(迪赛诺医药)0.6g*10盒上海迪赛诺医药集团股份有限公司78H20203589非基药171642105202泛昔洛韦胶囊(仙林钠)125mg*6粒盒大连美罗大药厂12.34H19991099非基药1034161052041奥司他韦胶囊（达菲）75mg*10盒上海罗氏制药有限公司171.55HJ20140344；HJ20140828基药国家1445151052043(集)磷酸奥司他韦胶囊(琦昕)75mg*10盒石药集团欧意药业有限公司18.11H20213670基药国家173897105206(临)玛巴洛沙韦片(速福达20mg)20mg*2盒上海罗氏制药有限公司222.36国药准字HJ20210027非基药1733021060012(集)甲硝唑片0.2g*100瓶四川科伦药业股份有限公司8.19H20057236基药国家161516107002盐酸小檗碱片(黄连素)0.1g*100片瓶东北制药集团公司沈阳第一制药厂23.73H21022453基药国家1138021070212板蓝根颗粒（无蔗糖）3g*20袋安徽九方制药有限公司13.85Z34020079基药国家141935107100(临)和血明目片0.3g*120盒西安碑林药业股份有限公司66.68Z20025067非基药201487108000制霉素片50万u*100瓶浙江震元制药有限公司39H33021393非基药1312031080014(集)氟康唑片(康锐)50mg*24盒扬子江药业集团有限公司5.47H19990151基药国家202589108005伊曲康唑胶囊(斯皮仁诺)0.1g*14粒盒西安扬森制药有限公司94.86H20020367基药国家1314991080054(集)盐酸伊曲康唑胶囊(克银迪)0.1g*14盒上海现代哈森(商丘)药业有限公司15.4H20070141基药国家205001108007(集)伏立康唑片(匹纳普)50mg*10盒北京博康健基因科技公司119.86H20055751非基药112936109000(集)异烟肼片0.1g*100盒杭州民生药业有限公司3.98H33021636基药国家155012109001(集)乙胺丁醇片 0.25g*100片瓶杭州民生药业有限公司12.5H33021602基药国家1710991090031利福喷丁胶囊0.15g*20粒盒无锡福祈制药有限公司49.1H10940012非基药1398091090033(集)利福平胶囊0.15g*100盒江苏悦兴药业有限公司25.66H32020147基药国家203987109005(集)吡嗪酰胺片0.25g*100片瓶沈阳红旗制药有限公司19.49H21022354基药国家1242471110051胞磷胆碱钠片0.2g*20盒福建闽东力捷迅药业有限公司46.17H20100008非基药136507111006吡拉西坦片0.4g*100片瓶杭州民生药业有限公司19.32H33021967非基药1374611110123(集)盐酸多奈哌齐片5mg*28盒浙江华海药业股份有限公司28H20183417非基药1688851110124氢溴酸加兰他敏片(金康灵力)5mg*30盒浙江金华康恩贝生物制药有限公司158.19国药准字H20030957非基药1371351120014盐酸曲马多缓释片(舒敏)0.1g*10盒意大利Farmaceutici Formenti S.p.A34.92进口注册证号H20140977非基药1130004(集)硫酸氨基葡萄糖胶囊（伊索佳）0.314g*24盒浙江海正药业股份有限公司7.81H20041316非基药143769113007复方对乙酰氨基酚片Ⅱ(散利痛)10片盒拜耳医药保健有限公司(北京)5.79H20056948非基药1165991130081酚麻美敏片(泰诺)20片盒上海强生制药有限公司13.47H20010115非基药1364991130191(集)布洛芬缓释胶囊0.3g*24盒南京易亨制药有限公司5.39国药准字H20203355基药国家1711021130192(集)对乙酰氨基酚片0.5g*100瓶四川省通园制药集团有限公司5.59国药准字H20057276基药国家1670001130194(集)美洛昔康片(宏强)7.5mg*20盒扬子江药业集团有限公司5.37国药准字H20100207非基药1566861130196塞来昔布胶囊(西乐葆)0.2g*6粒盒辉瑞制药分包装（Pfizer Pharmaceuticals LLC）27.54HJ20140106非基药1469781130198(集)塞来昔布胶囊0.2g*30瓶石药集团欧意药业有限公司9.38国药准字H20203297非基药171142113020汉防己甲素片20mg*12盒金华康恩贝生物制药有限公司53.86H33022075非基药1373131130232治伤胶囊0.25*42盒浙江康润制药有限公司27.2Z10920013非基药136972113027(集)非布司他片40mg*16盒江苏万邦生化医药有限公司16.48国药准字H20130058非基药171158113028秋水仙碱片(舒风灵)1mg*20盒昆药集团股份有限公司11.32H53021534非基药122756113029苯溴马隆片(尔同舒)50mg*10盒宜昌东阳光长江药业股份有限公司18.77H20040348基药国家1074921130291苯溴马隆片(立加利仙)50mg*10盒昆山龙灯瑞迪制药有限公司22.93HJ20171302基药国家146270113030氨酚双氢可待因片500mg/10mg*24盒陕西九州制药有限责任公司37.16H20073626非基药102772113100乙哌立松片(妙纳)50mg*20盒卫材(中国)药业有限公司24.93H20133175非基药157216113200盐酸替扎尼定片2mg*24盒四川科瑞德制药有限公司47.44H20060645非基药120270114000盐酸苯海索片2mg*100瓶江苏天士力帝益药业有限公司23.73H32023129基药国家102054114002多巴丝肼片(美多巴)200mg/50mg*40盒上海罗氏制药有限公司75.56H10930198基药国家1444961140022(临)(达灵复)恩他卡朋双多巴片Ⅱ100mg:25mg:200mg*30瓶芬兰Orion Corporation230.01HJ20171148非基药1497511140023(临)卡左双多巴缓释片(息宁)50mg/200mg*30盒杭州默沙东制药有限公司分包装49.67国药准字HJ20160371非基药146053114003盐酸司来吉兰片(咪多吡)5mg*100瓶芬兰Orion Corporation320.99H20160342非基药1321761140032(集)甲磺酸雷沙吉兰片(神百定)1mg*28盒浙江华海药业股份有限公司25.76H20243784非基药209587114004甲磺酸溴隐亭片2.5mg*30瓶意大利诺华制药有限公司91.47HJ20160030基药国家1473251140061(集)盐酸普拉克索片(齐舒宁)0.25mg*30盒齐鲁制药（海南）有限公司15.11H20203724基药国家171670114012(帕瑞可)酒石酸伐尼克兰片1mg*14盒江苏嘉逸医药有限公司144.38国药准字H20233180非基药202758115000盐酸氯丙嗪片25mg*100瓶常州康普药业有限公司11H32022161基药国家133557115002(集)氯氮平片25mg*100瓶江苏恩华药业股份有限公司3.47H32022963基药国家102491115003(黛力新)氟哌噻吨美利曲辛片0.5mg/10mg*20盒丹麦Hlundbeck A/S45.66H20171104非基药1445241150031(集)(圣美弗)氟哌噻吨美利曲辛片0.5mg/10mg*30盒重庆圣华曦药业股份有限公司33.38H20153122非基药1766551150044(集)奥氮平片(又悦)5mg*28盒浙江华海药业股份有限公司17.35H20203557基药国家1715581150052(集)利培酮片(索乐)1mg*60盒浙江华海药业股份有限公司3.87H20052330基药国家1080871150053利培酮口崩片(单克)1mg*20盒常州四药制药有限公司19.99国药准字H20080286非基药1372091150064(集)米氮平片(希洛宁30mg)30mg*28盒印度Aurobindo Pharma Limited58.58国药准字HJ20220080非基药2005201150082(集)富马酸喹硫平片0.1g*20盒合肥英太制药有限公司19.16国药准字H20203367基药国家171146115011盐酸阿米替林片25mg*100瓶常州四药制药有限公司19.21H32023764基药国家137547115012盐酸曲唑酮片(美时玉)50mg*20盒台湾美时化学制药股份有限公司51.19HC20171014非基药1474021150132(集)盐酸度洛西汀肠溶胶囊30mg*14盒青岛百洋制药有限公司11.25H20203675非基药1717901150133(集)枸橼酸坦度螺酮片10mg*63盒兰西哈三联制药有限公司6.56国药准字H20234382基药国家2135731150142(集)(乐朋)草酸艾司西酞普兰片10mg*56盒浙江华海药业股份有限公司65.75H20193308非基药176346115016奋乃静片4mg*100瓶上海朝晖药业有限公司46.78H31021084非基药1180001160001地西泮片2.5mg*20盒华中药业股份有限公司9.8H42021528基药国家116001奥沙西泮片(启捷)15mg*14盒湖南洞庭药业股份有限公司42.95国药准字H20253141非基药1160012艾司唑仑片1mg*20盒华中药业股份有限公司11H42021522基药国家1160013劳拉西泮片1mg*14盒湖南洞庭药业股份有限公司19.8国药准字H20031065非基药1160021氯硝西泮片2mg*20瓶江苏恩华药业股份有限公司10.6H10930004基药国家1160031阿普唑仑片0.4mg*20盒江苏恩华药业股份有限公司6H32020215基药国家1160061酒石酸唑吡坦片(思诺思)10mg*7盒赛诺菲（杭州）制药有限公司20.78HJ20181237基药国家116007苯巴比妥片30mg*100瓶上海信谊药厂有限公司48H31022038基药国家116010谷维素片10mg*100瓶杭州益品新五丰药业有限公司21.79H33021418非基药1397011170010盐酸氯米帕明片(恩华药业)25mg*50瓶江苏恩华药业股份有限公司15.07国药准字H32022974基药国家1026911170013(集)氢溴酸西酞普兰片(喜太乐)20mg*14盒四川科伦药业股份有限公司32.84国药准字H20041200非基药1071521170014五氟利多片(恩华药业)20mg*24瓶江苏恩华药业股份有限公司49.8国药准字H32022976非基药1025241170015帕利哌酮缓释片(欧舒安)3mg*30瓶石药集团欧意药业有限公司475.58国药准字H20233701基药国家2046631170016(集)阿立哌唑口崩片(索清宁)5mg*60盒浙江华海药业股份有限公司22.47国药准字H20213878基药国家1746891170018(集)氨磺必利片(百优林)200mg*20盒厦门力卓药业有限公司30.98国药准字H20203565基药国家1714831170019氟哌啶醇片2mg*100瓶宁波大红鹰药业股份有限公司27.27H33020585基药国家1106971170021盐酸丁螺环酮片(一舒)5mg*100瓶江苏恩华药业股份有限公司55.05国药准字H19991024基药国家2058461170022盐酸齐拉西酮胶囊(思贝格)20mg*20盒江苏恩华药业股份有限公司43.4国药准字H20061142非基药1026221170033(集)盐酸帕罗西汀片(乐友)20mg*30盒浙江华海药业股份有限公司35.7H20031106基药国家1726951170041盐酸文拉法辛胶囊25mg*24盒苏州第四制药厂有限公司23.98H20084496基药国家1041181170042(集)盐酸文拉法辛缓释胶囊(文悦思)75mg*14盒北京福元医药股份有限公司35.8H20143052基药国家1584251170061(集)盐酸氟西汀胶囊(奥麦伦)20mg*14盒上海上药中西制药有限公司30.66国药准字H19980114基药国家1416071170071(集)盐酸舍曲林片(乐元)50mg*28盒浙江华海药业股份有限公司20.16国药准字H20080141非基药103170117010马来酸氟伏沙明片(瑞必乐)50mg*30盒丽珠集团丽珠制药厂64.32H20058921非基药105139117020碳酸锂缓释片(恩华药业)0.3g*100瓶江苏恩华药业股份有限公司58.6国药准字H10900013非基药102512117021丙戊酸镁缓释片(神泰)0.25g*30瓶湖南省湘中制药有限公司40.28H20030537非基药142333118001卡马西平片 0.1g*100瓶江苏鹏鹞药业有限公司25H32021018基药国家1333171180011卡马西平片(得理多)0.2g*30盒北京诺华制药有限公司25.13H11022279基药国家131508118003丙戊酸钠片0.2g*100瓶湖南湘中制药有限公司17.8H43020874基药国家1426871180032丙戊酸钠缓释片(Ⅰ)(德巴金)0.5g*30瓶赛诺菲（杭州）制药有限公司60.3H20010595非基药147105118005(集)加巴喷丁胶囊0.3g*10盒江苏恒瑞医药股份公司2.77H20050271非基药135578118006拉莫三嗪片(利必通)50mg*30盒波兰葛兰素史克85.87HJ20160513基药国家147487119001(集)普瑞巴林胶囊75mg*8盒华润双鹤药业股份有限公司19.27H20203550非基药171530120000地高辛片0.25mg*30盒上海上药信谊药厂有限公司23.38H31020678基药国家1363121210002(集)盐酸普罗帕酮片50mg*100瓶浙江亚太药业股份有限公司9.72H33020108基药国家1399811210050盐酸胺碘酮片(可达龙)0.2g*10盒赛诺菲（杭州）制药有限公司22.78HJ20181050基药国家176856121006(临)盐酸拉贝洛尔片0.1g*30盒江苏迪赛诺制药有限公司72H32026119非基药1392791210071(集)盐酸普萘洛尔片10mg*100瓶华中药业股份有限公司19.8H42022488基药国家1023151220002硝酸甘油片0.5mg*100瓶北京益民药业有限公司35.2H11021022基药国家134391122001硝酸异山梨酯片 5mg*100瓶上海衡山药业有限公司18.47H31021357基药国家141473122002阿魏酸哌嗪片50mg*50盒湖南康普药业有限公司8.29H43021760非基药1470911220041(集)单硝酸异山梨酯片20mg*48盒山东方明药业集团股份有限公司20.21H20067336基药国家1389801220064(集)盐酸曲美他嗪片20mg*30盒瑞阳制药有限公司2.59国药准字H20066534非基药110382122011复方丹参片60粒瓶台州南峰药业公司14.49Z33020428非基药1325241220122(集)复方丹参滴丸27mg*180瓶天津天士力制药股份有限公司22.18Z10950111基药国家1039491220161通心络胶囊0.26g*40瓶石家庄以岭药业有限公司33.07Z19980015基药国家1143151220411氟桂利嗪胶囊(西比灵)5mg*20盒西安扬森制药有限公司15.78H10930003基药国家1313711220413(集)(雅齐施)盐酸氟桂利嗪片5mg*60盒潍坊中狮制药有限公司3.78H20023860基药国家10665112204312(敏使朗)甲磺酸倍他司汀片(拆零)6mg*100盒卫材(中国)药业有限公司36.02国药准字H20040130非基药15410112204413(集)血塞通胶囊(维和)50mg*90盒云南维和药业股份有限公司38.4Z53021143基药国家2049631220443(集)地奥司明片0.45g*24盒马应龙药业集团股份有限公司15.3H20066737非基药111837122052珍宝丸0.2g*60盒内蒙古蒙药股份有限公司25.74Z15020410非基药129280122053丁苯酞软胶囊(恩必普)0.1g*24盒石药集团恩必普药业有限公司77.76H20050299非基药106156123003地尔硫卓片30mg*100盒浙江亚太药业股份有限公司28.8H33020112基药国家139248123005硝苯地平片10mg*100瓶上海信谊天平药业有限公司3.2H31021222基药国家1408911230054(集)硝苯地平控释片30mg*21盒华润双鹤利民药业(济南)有限公司9.96H20223465非基药1768061230061(集)硝苯地平缓释片(Ⅱ)20mg*60盒迪沙药业集团有限公司3.77H20083792基药国家1572261230072(集)尼莫地平片20mg*50瓶宁波大红鹰药业股份有限公司3.08H33020540基药国家1106281230073(临)尼莫地平注射液(尼膜同)50ml:10mg瓶德国Solupharm Pharmazeutische Erzeugnisse GmbH106.4HJ20181106非基药209523123009非洛地平缓释片(波依定)5mg*10盒阿斯利康制药有限公司19.81H20030415基药国家1305021230112(集)(依恒)非洛地平缓释片5mg*48盒石家庄四药有限公司9.98H20223964基药国家204119123012(络活喜)苯磺酸氨氯地平片5mg*7盒晖致制药(大连)有限公司21.61国药准字H10950224基药国家10188212301241(集)苯磺酸氨氯地平片(京新)5mg*28盒浙江京新药业股份公司1.68H20103356基药国家1652361230126(集)苯磺酸左氨氯地平片2.5mg*28片盒扬子江药业上海海尼药业有限公司12.89H20103342基药国家2039271230131(多达一)氨氯地平阿托伐他汀钙片5mg/10mg*7盒瀚晖制药有限公司30.99H20217056非基药1766821230132(临)氨氯地平贝那普利片(Ⅱ)5mg:10mg*10盒成都地奥制药有限公司38.41H20090309非基药1468461230133(集)(海慧通)氨氯地平阿托伐他汀钙片5mg:10mg*14盒宁波美诺华天康药业有限公司35.76H20223037非基药203413123100(集)卡托普利片25mg*100瓶上海旭东海普药业有限公司3.5国药准字H31020564基药国家139764123103贝那普利片(洛汀新)10mg*14盒北京诺华制药有限公司31.35H20030514非基药1314391231031(集)盐酸贝那普利片(信达怡)10mg*14盒深圳信立泰药业股份有限公司6.61H20043648非基药139568123105马来酸依那普利叶酸片10mg/0.8mg*7盒深圳奥萨制药有限公司21.28H20103723基药国家116483123200(集)厄贝沙坦片(安来)75mg*28盒浙江华海药业股份有限公司4.46H20030016非基药1031801232002厄贝沙坦片(安博维)150mg*7盒赛诺菲（杭州）制药有限公司22.24H20040494非基药1747391232014沙库巴曲缬沙坦钠片(诺欣妥)100mg*14盒北京诺华制药分包装（新加坡）42.56国药准字HJ20170363非基药1629541232015(集)缬沙坦片40mg*28盒浙江华海药业股份有限公司2.8国药准字H20183128非基药163346123203氯沙坦钾片(科素亚)50mg*7盒杭州默沙东制药有限公司31.5HJ20171245，HJ20171246非基药1460781232031(海捷亚)氯沙坦钾氢氯噻嗪片50mg/12.5mg*7盒杭州默沙东制药有限公司26.66HJ20171067,HJ20171073非基药1460541232035(集)氯沙坦钾片(倍怡)50mg*28盒浙江华海药业股份有限公司15.12H20070264非基药1661131232037(集)氯沙坦钾氢氯噻嗪片50mg:12.5mg*28盒浙江华海药业股份有限公司4.16H20223466非基药1764471232041(安博诺)厄贝沙坦氢氯噻嗪片150mg/12.5mg*7盒赛诺菲（杭州）制药有限公司9.8HJ20140194非基药1471141232042(集)(依伦平14)厄贝沙坦氢氯噻嗪片150mg/12.5mg*14盒南京正大天晴制药有限公司9.8H20057227非基药1481241232053(集)替米沙坦片(舒尼亚)40mg*28盒北京福元医药股份有限公司12.89H20050996非基药133783123206(倍博特)缬沙坦氨氯地平片（I）80mg/5mg*7盒北京诺华制药有限公司分包装46.23HJ20150310基药国家1625111232062(集)(瑞心安)缬沙坦氨氯地平片(Ⅰ)80mg/5mg*14盒江苏恒瑞医药股份有限公司7.55H20203486基药国家202603123208奥美沙坦酯片(傲坦)20mg*7盒第一三共制药（上海）有限公司29.94H20060371非基药1000471232082(集)奥美沙坦酯片(兰沙)20mg*28盒北京福元医药股份有限公司29H20061312非基药207314123306酒石酸美托洛尔片(倍他乐克)25mg*20盒阿斯利康制药有限公司6.05H32025391基药国家1304371233062(倍他乐克)美托洛尔缓释片47.5mg*7盒阿斯利康制药有限公司13.47HJ20140780非基药1307311233063(集)酒石酸美托洛尔片(亚旭)50mg*30盒远大医药（中国）有限公司2.62H20073972基药国家1734591233064(集)琥珀酸美托洛尔缓释片(普洛)47.5mg*7盒浙江普洛康裕制药有限公司4.6H20213769非基药174671123310(集)富马酸比索洛尔片5mg*18盒成都苑东生物制药股份有限公司10.46国药准字H20083008基药国家113259123313(集)卡维地洛片(枢衡)12.5mg*24盒福安药业集团宁波天衡制药有限公司3.7H20052427非基药138741123501复方利血平氨苯蝶啶片10片盒华润双鹤药业股份有限公司12.98H11022335非基药119716123502地巴唑片10mg*100瓶天津力生制药股份有限公司6.79H12020227非基药1114711235031(集)吲达帕胺片2.5mg*30盒重庆药友制药有限责任公司1.59国药准字H50021320基药国家1658731235041盐酸可乐定片75ug*100瓶常州制药厂有限公司11H32021681非基药1032461240010海博麦布片(赛斯美)10mg*14盒浙江海正药业股份有限公司89.18国药准字H20210030非基药1738331240012苯扎贝特片(阿贝他)0.2g*20盒江苏天士力帝益药业有限公司16.6H20010013非基药101910124003瑞舒伐他汀钙片(可定)10mg*7片盒阿斯利康制药有限公司36.86HJ20160545基药国家1306711240035(拆零)瑞舒伐他汀钙片(可定)10mg*7盒阿斯利康制药有限公司36.86国药准字J20170008基药国家1306711240037(集)瑞舒伐他汀钙片(京诺)10mg*28盒浙江京新药业股份公司5.5H20080483基药国家1763141240043(集)辛伐他汀片(京必舒新)20mg*28盒浙江京新药业股份公司3.78国药准字H20000009基药国家137039124005阿托伐他汀钙片(立普妥)20mg*7盒晖致制药(大连)有限公司38.49国药准字H20051408基药国家1522251240054(拆零)(立普妥)阿托伐他汀钙片20mg*7盒晖致制药(大连)有限公司38.49国药准字H20051408基药国家1522251240055(集)(美达信10mg)阿托伐他汀钙片10mg*14盒齐鲁制药海南有限公司1.68H20193143基药国家165980124007(集)血脂康胶囊0.3g*24盒北京北大维信生物科技有限公司17.26国药准字Z10950029基药国家116506124009(集)依折麦布片(易辅之)10mg*30盒Lek Pharmaceuticals d.d38.89国药准字HJ20210050非基药1764261240091(集)依折麦布片(伊来恩)10mg*20盒北京福元医药股份有限公司25.97国药准字H20213584非基药176994129002盐酸米多君片（米维）2.5mg*20盒国药集团川抗制药有限公司39H20060551非基药1027911290032去氨加压素片(和悦)0.089mg*30盒海南中和药业股份有限公司115.86国药准字H20103402基药国家112014130000氢氯噻嗪片 25mg*100瓶常州制药厂有限公司23H32021683基药国家1031321300001氢氯噻嗪片(云鹏医药)25mg*100瓶云鹏医药集团有限公司6国药准字H14020796基药国家125000130001螺内酯片 20mg*100瓶杭州民生药业有限公司13.8H33020070基药国家137659130004(集)呋塞米片20mg*100瓶天津力生制药股份有限公司14.5国药准字H12020163基药国家1114801310011甲磺酸多沙唑嗪缓释片(可多华)4mg*10盒晖致制药(大连)有限公司54.79国药准字HJ20170175非基药146977131002非那雄胺片(保列治)5mg*10盒杭州默沙东制药有限公司39.36J20150143基药国家1460741310022(集)非那雄胺片(康恩贝)5mg*30盒杭州康恩贝制药有限公司5.21国药准字H20051921基药国家170799131005普乐安胶囊0.375g*120粒瓶浙江康恩贝制药股份有限公司21.87Z33020479基药国家143080131007(哈乐)盐酸坦索罗辛缓释胶囊0.2mg*10盒安斯泰来制药（中国）有限公司37.64H20000681基药国家147180131009(集)(齐索)盐酸坦索罗辛缓释胶囊0.2mg*20盒浙江仟源海力生制药有限公司8.97H20020623基药国家1392871310121热淋清颗粒（无糖型）4g*8盒贵州威门药业股份有限公司23.52Z52020383非基药112947131015(集)枸橼酸氢钾钠颗粒(金石淋)2.5g*40盒浙江施强制药有限公司62.72H20203639非基药1734961320011酒石酸托特罗定片2mg*14盒成都迪康药业有限公司18.48H20000609非基药1408511320022(集)(安他平)琥珀酸索利那新片5mg*14盒齐鲁制药有限公司16.8H20183497非基药1654901320041(集)米拉贝隆缓释片(石药)50mg*10盒石药集团中诺药业(石家庄)有限公4.79H20233665非基药2048721400011(集)盐酸氨溴索分散片(抒坦清)30mg*50盒山西仟源医药集团股份有限公司5.25国药准字H20060254基药国家1231591400031(集)盐酸氨溴索口服溶液(兰苏)100ml:0.6g瓶常州四药制药有限公司4.5H20000661非基药136086140004复方甘草片100片瓶宁波大红鹰药业股份有限公司9.4H33020888基药国家110659140006(集)桉柠蒎肠溶胶囊(切诺)0.3g*18盒北京九和药业有限公司24.75H20052401基药国家1282041400111复方氢溴酸右美沙芬糖浆100ml瓶湖北凤凰白云山药业有限公司20.52H20066647非基药1432531400112美愈伪麻口服溶液(阿贝赛)10ml*6盒江苏悦兴药业有限公司36H10950243非基药167566140014肺力咳合剂100ml瓶贵州健兴药业有限公司17.05Z20025136非基药1334031410001(万托林)硫酸沙丁胺醇吸入气雾剂100ug*200揿瓶西班牙Glaxo Wellcome S.A19.79HJ20150673基药国家132285141002茶碱缓释片 0.1g*24盒山东新华制药股份有限公司5.43H37020700基药国家1093251410041(博利康尼)硫酸特布他林雾化吸入用溶液5mg:2ml支瑞典ASTRAZENECE A B4.368H20140108非基药1322521410042(集)(恒托尼)硫酸特布他林雾化吸入用溶液5mg:2ml支江苏大红鹰恒顺药业有限公司1.15H20223363非基药1768671410051复方甲氧那明胶囊(阿斯美)60粒瓶第一三共制药（上海）有限公司37.48H20033669非基药1001221410062盐酸丙卡特罗片(拆零)25ug*40盒安徽环球药业股份有限公司24.53国药准字H34023109非基药1395701410201(信必可都保)布地奈德福莫特罗吸入粉雾剂(Ⅱ)160ug/4.5ug*60吸瓶瑞典,AstraZeneca AB SE-151 85,Sodertalje220.18HJ20140458基药国家132221141022(可必特)吸入用复方异丙托溴铵溶液2.5ml:(0.5mg/2.5mg)支法国勃林格殷格翰国际公司4.038H20150173非基药1473211410221(集)(普吸清)吸入用复方异丙托溴铵溶液2.5ml:(0.5mg/2.5mg)支四川普锐特药业有限公司1.45H20213089非基药1720261410251噻托溴铵粉雾剂(天晴速乐)18ug*10盒正大天晴药业集团股份有限公司55.56H20060454基药国家1186901410261(+)噻托溴铵粉雾剂+吸入器(天晴速乐)18ug*10盒正大天晴药业集团股份有限公司58.82H20060454基药国家1186631410271布地格福吸入气雾剂(倍择瑞)160/7.2/4.8ug*120揿瓶法国AstraZeneca Dunkerque Production233进口药品注册证号H20190063非基药1684541411011(集)孟鲁司特钠片(安必生)10mg*5盒杭州民生滨江制药有限公司4.96H20183239非基药1635351420021沙美特罗替卡松吸入粉雾剂(舒利迭)50ug/250ug*60泡盒葛兰素史克（法国）190.63H20150324非基药132271142004(令舒)吸入用布地奈德混悬液2ml:1mg支澳大利亚AstraZeneca Pty ltd12.938H20140475基药国家1323271420041(集)(普畅舒)吸入用布地奈德混悬液2ml:1mg支四川普锐特药业有限公司2.45H20213286基药国家172421142005(吸入富露施)吸入用乙酰半胱氨酸溶液3ml:0.3g支意大利Zambon S.P.A.13.3HJ20150548非基药1474601420050(集)(区坦)吸入用乙酰半胱氨酸溶液3ml:0.3g支福安药业集团庆余堂制药有限公司2.18H20223682非基药2050381420051(易安平)吸入用盐酸氨溴索溶液2ml:15mg支北京韩美药品有限公司8.5J20190023非基药1686051430001(集)至灵胶囊(长兴制药)0.25g*50瓶浙江长兴制药有限公司16.42Z33020212非基药1448171430002(集)至灵胶囊(圣博康)0.25g*60盒浙江圣博康药业有限公司10.8Z20163031非基药138855143002(集)百令胶囊0.5g*42盒杭州中美华东制药有限公司43.19Z10910036基药国家126585150000氯苯那敏片4mg*100瓶江苏鹏鹞药业有限公司9.49H32023645基药国家1333271500041(集)盐酸西替利嗪片(希瓦丁)10mg*24盒苏州中化药品工业有限公司2.95国药准字H20030447非基药1520231500043(集)盐酸左西替利嗪片5mg*14盒杭州民生药业有限公司2.11国药准字H20070312非基药1659181500067(集)依巴斯汀片(开思亭)10mg*10盒西班牙INDUSTRIAS FARMACEUTICAS ALMIRALL.S.A3.49进口药品注册证号HJ20140855非基药141592150009氯雷他定片(开瑞坦）10mg*6盒拜耳医药保健有限公司启东分公司（分装）14.98H10970410基药国家11098515000912氯雷他定糖浆0.1%*100ml瓶江苏广承药业有限公司18.67H20103533非基药13978215000914(集)氯雷他定片(雪苏)10mg*12盒扬子江药业上海海尼药业有限公司8.4H20080134基药国家1004941500094(集)地氯雷他定片(信敏汀)5mg*12盒深圳信立泰药业股份有限公司3.65H20020092非基药168882151000酮替芬片 1mg*60瓶江苏鹏鹞药业有限公司14.48H32023636非基药1334251600001(集)碳酸氢钠片0.5g*100瓶天津力生制药股份有限公司8.21H12020220基药国家11152916000051(集)铝碳酸镁咀嚼片0.5g*24盒广东华润顺峰药业有限公司5.7国药准字H20193054基药国家167008160004(丽珠得乐)枸橼酸铋钾胶囊120mg*40盒丽珠集团丽珠制药厂22.4国药准字H10920098基药国家2079561600082(集)奥美拉唑肠溶胶囊(海南)20mg*14瓶海南海灵化学制药有限公司2.07国药准字H10920092基药国家11590016001241(集)兰索拉唑肠溶片(达适)15mg*14盒华润双鹤利民药业(济南)有限公司1.81H20093543非基药13723916001271(集)泮托拉唑钠肠溶片(希洛施)40mg*30盒印度Aurobindo Pharma Limited19.86HJ20200063非基药1718011600130(波利特)雷贝拉唑钠肠溶片20mg*7盒卫材(中国)药业有限公司100.5国药准字H20090090非基药1571591600132(集)雷贝拉唑钠肠溶片(顺安然)20mg*28瓶江苏安必生制药有限公司11.98H20233484非基药2037331600134富马酸伏诺拉生片(沃克)20mg*7盒日本Takeda Pharmaceutical Company Limited, Hikari Plant69.3国药准字J20200011非基药169316160027L_谷氨酰胺/呱仑酸钠颗粒(麦滋林)0.67*15包袋日本寿制药株式会社19.8国药准字HJ20160619非基药1210051600312瑞巴派特片(膜固思达)0.1g*24片盒浙江大冢制药有限公司29.92H20020541非基药1401171600322替普瑞酮胶囊(施维舒)50mg*80盒卫材(中国)药业有限公司91.64H20093656非基药171584161000阿托品片0.3mg*100片瓶杭州民生药业有限公司18H33020086基药国家147627161001消旋山莨菪碱片5mg*100片瓶杭州民生药业有限公司15H33021706基药国家137566161003匹维溴铵片(得舒特)50mg*15盒法国Mylan Laboratories SAS25.31H20160396基药国家147529162002米曲菌胰酶片(慷彼申)20片盒康哲(湖南)制药有限公司分包装38.68国药准字HJ20170092非基药171639162003复方消化酶胶囊(达吉)20粒盒韩国韩林制药株式传神会社34.02H20181242非基药1416411620031(千红怡美)复方消化酶胶囊（Ⅱ）20粒盒常州千红生化制药有限公司31.31H20051951非基药1449891620032(集)复方消化酶胶囊20粒盒北京星昊医药股份有限公司28.24H20064646非基药1247501630032(集)复方嗜酸乳杆菌片(益君康)0.5g*24盒通化金马药业集团股份有限公司32.44H10940114非基药111965163004(丽珠肠乐)双歧杆菌活菌胶囊0.5亿*20粒盒丽珠集团丽珠制药厂22.03S10960040非基药1051191630051(集)(贝飞达)双歧杆菌三联活菌肠溶胶囊210mg*36盒晋城海斯药业有限公司26.4S19993065非基药1004901630061(思连康)双岐杆菌四联活菌片0.5g*24盒杭州远大生物制药有限公司24.3S20060010非基药135734163007(美常安)枯草杆菌二联活菌肠溶胶囊0.25g*20粒盒北京韩美药品有限公司20.86S20030087基药国家121869163012美沙拉秦缓释颗粒(艾迪莎)0.5g*10包盒上海爱的发制药公司46.56H20143164基药国家162234164000(能全力)肠内营养混悬液(TPF)500ml瓶纽迪希亚(无锡)制药公司38.87H20010284非基药130349164005(瑞代)肠内营养乳剂(TPF-D)500ml瓶费森尤斯卡比华瑞制药有限公司59.06H20183301非基药166357164008(瑞易西)肠内营养乳剂(SP)500ml袋费森尤斯卡比华瑞制药有限公司68.4H20213644非基药175738165001盐酸昂丹司琼片4mg*12盒齐鲁制药有限公司87.31H10970062基药国家1139501650012(集)多潘立酮片10mg*30盒华东医药(西安)博华制药有限公司4.18H20093043基药国家113684165002西甲硅油乳剂(柏西)30ml瓶德国柏林化学股份公司32.4HJ20160184非基药1322431650032(集)枸橼酸莫沙必利片(快力)5mg*36盒鲁南贝特制药有限公司18.6H19990317基药国家1310001650041曲美布汀片(援生力维)0.1g*30盒信合援生制药股份有限公司16.06H20000388非基药1088091650052胃复春胶囊0.35g*60瓶杭州胡庆馀堂药业有限公司67.5Z20090697非基药168207166002芦比前列酮软胶囊24ug*14瓶南京正大天晴制药有限公司63.28H20233802非基药2048821660031(集)聚乙二醇4000散10g*10袋盒马应龙药业集团股份有限公司7.39国药准字H20080092基药国家111933166004(集)复方聚乙二醇电解质散(Ⅰ)69.56g(3包）盒江西恒康药业有限公司5.56H20020031非基药139031166006(集)复方聚乙二醇电解质散(Ⅲ)(拉米汀)复方*4袋盒山东鲁盛制药有限公司12.67国药准字H20234520非基药207143167001联苯双酯片25mg*20瓶河北东风药业公司55.86国药准字H13023295基药国家1715511670083(美能)复方甘草酸苷片100片盒卫材(中国)药业有限公司118.55HJ20171325,HJ20171326非基药1295301670085(集)复方甘草酸苷片100片盒北京凯因科技股份有限公司11.97H20083001非基药1368051670092甘草酸二铵肠溶胶囊(天晴甘平)50mg*63盒正大天晴药业集团股份有限公司55.94H20040628非基药1623361670094多烯磷脂酰胆碱胶囊(易善复)228mg*24盒赛诺菲(北京)制药有限公司37.76H20059010非基药1023791670095水飞蓟素胶囊(利加隆)140mg*10盒德国MADAUS GmbH辉瑞制药有限公司分包装28.2国药准字HJ20181067基药国家300411167012拉米夫定片(贺普丁)0.1g*14盒重庆药友制药有限责任公司128.3H20030581非基药1027551670121拉米夫定片(健甘灵)0.1g*14盒湖南千金湘江药业股份有限公司61.45H20103481非基药11853516701321(集)阿德福韦酯片(亿来芬)10mg*30瓶齐鲁制药有限公司7.95H20080032非基药16419516701361(集)恩替卡韦分散片(瑞夫恩)0.5mg*21盒苏州东瑞制药有限公司3.5H20100129基药国家1659911670141(临)先诺欣(先诺特韦片/利托那韦片组合包装)(0.375g*4+0.1g*2)*5盒先声药业有限公司479H20230001非基药3003941670153(集)乳果糖口服溶液(利动)15ml*10盒辽宁大熊制药有限公司41.25H20065730非基药176796167018谷胱甘肽片（阿拓莫兰）0.1g*36瓶重庆药友制药有限责任公司59.21H20050667非基药1080441670221(集)(优思弗)熊去氧胆酸胶囊0.25g*25粒盒德国福克大药厂136.92H20181059非基药1445251670222(集)(吡福)熊去氧胆酸片0.25g*24盒武汉普元药业有限责任公司73.21国药准字H20123209非基药148999171001叶酸片5mg*100瓶天津力生制药股份有限公司2.89H12020215基药国家1115841710012叶酸片0.4mg*31瓶江苏联环药业股份有限公司3.4H20044917基药国家103687171002(集)叶酸片5mg*30盒济南永宁制药股份有限公司1.14国药准字H20243422基药国家2094381710036(集)甲钴胺片(弥可保)(拆零)0.5mg*100盒卫材(中国)药业有限公司15.49H20143107非基药169902171004(集)(力蜚能)多糖铁复合物胶囊150mg*10盒美国Kremers Urban Pharmaceuticals Inc28.18HJ20150626非基药1765201720012鲨肝醇片20mg*100片瓶江苏鹏鹞药业有限公司42.5H32023581非基药1335031720031利可君片20mg*48盒江苏吉贝尔药业有限公司47.99H32025444非基药137208173001阿司匹林肠溶片(拜阿司匹灵)100mg*30盒拜耳医药保健有限公司(北京)13.55HJ20160685基药国家1470351730011(拆零)阿司匹林肠溶片(拜阿司匹灵)100mg*30盒拜耳医药保健有限公司13.55J20171021基药国家147035173003(集)阿司匹林肠溶片(济创)100mg*30盒烟台鲁银药业有限公司1.45国药准字H20234177非基药206240173004(波立维)硫酸氢氯吡格雷片75mg*7盒赛诺菲（杭州）制药有限公司24.8H20056410基药国家2025441730042(集)(恩存)硫酸氢氯吡格雷片75mg*14盒石药集团欧意药业有限公司12.18H20193160基药国家1660591730043(拆零)硫酸氢氯吡格雷片(波立维)75mg*7盒赛诺菲（杭州）制药有限公司24.8J20180029基药国家147104173005替格瑞洛片(倍林达)90mg*14盒阿斯利康制药有限公司(瑞典 AstraZeneca AB)94.64国药准字H20217033基药国家1762471730052(拆零)替格瑞洛片(倍林达)90mg*14盒阿斯利康制药有限公司(瑞典 AstraZeneca AB)94.64J20171077基药国家1762471730054(集)替格瑞洛片(欧意药业)90mg*60盒石药集团欧意药业有限公司53.03国药准字H20193166基药国家1711401730152(集)利伐沙班片(苏富乐)15mg*7盒苏州第三制药厂有限责任公司83.58H20213399基药国家1732881730153(集)利伐沙班片(东陽光)10mg*30盒广东东阳光药业股份有限公司4.8H20213374基药国家1733741740012(集)蚓激酶肠溶胶囊(普恩复60万u)60万u*12盒青岛国大药业有限公司6.98H20068081非基药1369841740013(集)蚓激酶肠溶胶囊(普恩复30万u)30万u*24盒青岛国大药业有限公司8.01国药准字H37022072非基药136983174003华法林钠片2.5mg*60瓶上海信谊九福药业有限公司18H31022123基药国家137349180000泼尼松片5mg*100片瓶浙江仙琚制药股份有限公司6.28H33021207基药国家1413511800021(集)甲泼尼龙片(欣甲龙)4mg*30盒山东鲁抗医药集团赛特有限责任公司10.8H20213671基药国家173901180003地塞米松片0.75mg*100片瓶浙江仙琚制药股份有限公司10.8H33020822基药国家141355182002戊酸雌二醇片(补佳乐)1mg*21片盒拜耳医药保健有限公司广州分公司27.85J20171038非基药1208921820021地屈孕酮片(达芙通)10mg*20盒荷兰Abbott BiologicalsB.V.107.92国药准字HJ20170221非基药1473081820022地诺孕素片(金舒安)2mg*28盒华润紫竹药业有限公司248国药准字H20213831非基药174550182004(临)(芬吗通1mg)雌二醇片/雌二醇地屈孕酮片复合包装1mg/1mg:10mg*28盒荷兰Abbott Healthcare Prodcts B.V.96.69H20150346非基药1473091820041(芬吗通2mg)雌二醇片/雌二醇地屈孕酮片复合包装2mg/2mg:10mg*28盒荷兰Abbott Healthcare Prodcts B.V.97进口注册证号H20150345非基药1473101820072黄体酮软胶囊(来婷)100mg*30盒浙江医药股份有限公司新昌制药厂70.95H20040982非基药104242184000炔诺酮片625ug*100片瓶上海信谊天平药业有限公司39H31021769非基药140963184001醋酸甲地孕酮分散片160mg*10片盒青岛国海生物制药有限公司81.51H20010074非基药139073184004(临)屈螺酮炔雌醇片(优思明)3mg/0.03mg*21盒拜耳医药保健有限公司广州分公司108HJ20170317非基药120909184005(临)替勃龙片(利维爱)2.5mg*7盒荷兰欧加农公司38.41进口注册证号H20160575非基药147290185001米非司酮片25mg*6片盒浙江仙琚制药股份有限公司10.8H10950347基药国家1415471850022(集)米索前列醇片(紫竹)0.2mg*3片盒华润紫竹药业有限公司4.01H20000668基药国家1371671860023鲜益母草胶囊0.4g*24盒浙江大德药业有限公司42.07Z20080052非基药137073187002(集)格列美脲片(佑苏)2mg*60盒扬子江药业广州海瑞制药4.72国药准字H20073592基药国家1670061870025格列美脲片(亚莫利)2mg*15片盒赛诺菲(北京)制药有限公司44.8H20057672基药国家1023841870031格列齐特片Ⅱ80mg*60片盒浙江京新药业股份公司16.69H19983058基药国家1373111870034(集)格列齐特缓释片(利宁格)30mg*60盒北京福元医药股份有限公司23.4H20066231非基药1337941870046(集)格列吡嗪控释片(易希)5mg*14盒南京易亨制药有限公司11.66H20203391非基药1713051870051格列喹酮片(糖适平)30mg*30片瓶北京万辉双鹤药业有限公司31.26H10940258基药国家1189481870065(集)盐酸二甲双胍片0.25g*60瓶寿光富康制药有限公司1.8国药准字H31020246基药国家1409541870066(集)盐酸二甲双胍缓释片(亿恒)0.5g*36盒南京亿华药业有限公司4.1国药准字H20040816基药国家1110741870068(临)(平慧安)二甲双胍恩格列净片(Ⅰ)500mg:5mg*60瓶齐鲁制药有限公司58.5国药准字H20244031非基药209829187010瑞格列奈片(诺和龙)1mg*30片盒德国勃林格殷格翰制药有限公司37.41进口药品注册证号H20171153基药国家1475001870102(集)瑞格列奈片(北京福元）0.5mg*60盒北京福元医药股份有限公司7.84H20133017基药国家1717821870134(集)盐酸吡格列酮片(瑞彤)30mg*30盒江苏德源药业股份有限公司15.6H20110048基药国家176870187014达格列净片(安达唐)10mg*14盒阿斯利康制药有限公司61.04国药准字H20234463基药国家2068301870142(临)脯氨酸恒格列净片(瑞沁)10mg*10盒江苏恒瑞医药股份有限公司59.3国药准字H20210053非基药174730188000(集)(拜唐苹50mg)阿卡波糖片50mg*30片盒拜耳医药保健有限公司7.51H19990205基药国家1165481880002(集)(拜唐苹0.1g)阿卡波糖片0.1g*30盒拜耳医药保健有限公司12.77H20010716非基药152129188001伏格列波糖片(倍欣)0.2mg*30片盒天津武田药品有限公司29.88H20010308非基药1151481880012(集)伏格列波糖片(华怡平)0.2mg*60盒苏州中化药品工业有限公司8.77H20093758非基药1520201880021(集)(伊衡)依帕司他片50mg*12盒山东达因海洋生物制药股份有限公司14.39H20050893非基药1373771880023(集)(德源)依帕司他片50mg*30盒江苏德源药业股份有限公司3.29国药准字H20213958非基药213482188006(临)磷酸瑞格列汀片(瑞泽唐)100mg*7盒江苏恒瑞医药股份有限公司29.4国药准字H20230018非基药204820189001左甲状腺素钠片(优甲乐)50ug*100片盒默克制药(江苏)有限公司24.88H20140052基药国家2073401890041丙硫氧嘧啶片50mg*100瓶上海朝晖药业有限公司39H31021082基药国家1179541890051甲巯咪唑片(赛治)10mg*50盒默克制药(江苏)有限公司26.6H20205041非基药173466189006(集)盐酸西那卡塞片(迪诺平)25mg*20盒北京百奥药业有限责任公司59H20213248基药国家173435190003(集)碳酸钙D3片(Ⅰ)(钙尔奇Ｄ)600mg*30片瓶赫力昂(苏州)制药有限公司19.88国药准字H10950029非基药1469511900063(集)(盖诺真40粒)阿法骨化醇软胶囊0.25ug*40盒青岛国信制药有限公司34.96国药准字H19991114基药国家123273190007(集)(罗盖全)骨化三醇胶丸0.25ug*10粒盒德国Catalent Germany Eberbach GmbH32.01HJ20140598非基药2048221900074(集)(盖生源)骨化三醇软胶囊0.25ug*20盒河南泰丰生物科技有限公司12.97H20227154非基药204010190009阿仑膦酸钠片(福善美)70mg*1片盒杭州默沙东制药有限公司58.46J20160100基药国家1460771900093阿仑膦酸钠片(安仑)70mg*4盒北京福元医药股份有限公司37.07H20059029基药国家133792190010四烯甲萘醌软胶囊(固力康)15mg*30盒卫材(中国)药业有限公司84国药准字J20150113非基药1298491900213(集)鲑降钙素鼻喷雾剂(金尔力)20ug*28喷瓶银谷制药有限责任公司99.85H20030905基药国家130031191000维生素B1片10mg*100片瓶广东恒健制药有限公司4.13H44020620非基药156831191002维生素Ｂ2片5mg*100片瓶广东恒健制药有限公司13.1H44020621基药国家156835191003(集)维生素Ｂ6片10mg*100片瓶杭州民生药业有限公司7.41国药准字H33022505基药国家163946191005复合维生素Ｂ片100片瓶江苏鹏鹞药业有限公司9H32023635非基药133424191006呋喃硫胺片25mg*100片瓶杭州民生药业有限公司13.8H20023738非基药137352192000维生素Ｃ片0.1g*100片瓶浙江瑞新药业股份有限公司13.57H33021139非基药1431661920031维生素E软胶囊(来益)0.1g*60瓶浙江医药股份有限公司新昌制药厂28.86H20003539非基药129457192004(福斯利诺)碳酸镧咀嚼片0.5g*20瓶英国HamolLimited222.2H20171351非基药147471192005(集)碳酸镧咀嚼片(迈诺恩)500mg*45瓶南京正大天晴制药有限公司129.15H20223690非基药207286192006复方氨基酸胶囊(8-11)0.35g*30粒盒深圳万和制药有限公司46H20000478非基药139030195001(集)复方α酮酸片(开同)0.63g*100片盒北京费森尢斯卡比医药有限公司190.4H20041442非基药1215561950021(集)复方α-酮酸片(雪特)0.63g*96盒河北天成药业股份有限公司28.26国药准字H20090263非基药113190195003罗沙司他胶囊(爱瑞卓20mg)20mg*3盒珐博进(中国)医药技术开发有限公司74.7H20180023非基药1656821950031罗沙司他胶囊(爱瑞卓50mg)50mg*3盒珐博进(中国)医药技术开发有限公司150.66H20180024非基药165671200000羟基脲片(HU)0.5g*100片瓶齐鲁制药有限公司46H37021289基药国家1145342000041他莫昔芬片10mg*60片瓶扬子江药业集团有限公司64.5H32021472基药国家100972200005比卡鲁胺片(康士得)50mg*28片盒阿斯利康制药有限公司868.83HJ20140720非基药1306662000053(集)比卡鲁胺片(艾易达)50mg*28盒浙江海正药业股份有限公司113.54H20073877非基药173379200006(希罗达)卡培他滨片0.5g*12片盒上海罗氏制药有限公司243.1H20073024基药国家1445162000061(集)卡培他滨片(卓仑)0.5g*12盒齐鲁制药有限公司22.14国药准字H20133361基药国家1546332000102(临)来曲唑片(芙瑞)2.5mg*10盒江苏恒瑞医药股份有限公司21.14H19991001基药国家1355842000112(集)替吉奥胶囊20mg*42盒江苏恒瑞医药股份有限公司218.96国药准字H20100135非基药135617200014甲氨蝶呤片2.5mg*16瓶上海上药信谊药厂有限公司33.28H31020644基药国家1587222010051胚宝胶囊0.3g*30粒盒浙江康德药业有限公司24.31Z33020207非基药13714820110211(集)硫酸羟氯喹片(赛西福)0.2g*30盒福建海西新药创制药股份有限公司11.89国药准字H20234411基药国家2134182011023(集)吗替麦考酚酯片0.5g*100瓶浙江海正药业股份有限公司160H20070082基药国家176854201105沙利度胺片(反映亭)50mg*20瓶常州制药厂有限公司61.1H32026130非基药1032862011061(集)来氟米特片(施尼平)10mg*30盒齐鲁制药有限公司13.8H20203194基药国家169342202003阿苯达唑片(肠虫清)0.2g*10片盒中美天津史克制药有限公司8.83H12020496基药国家1173172100003(集)氯化钾缓释片(补达秀)0.5g*48盒广州誉东健康制药有限公司10.99H20178003基药国家173341210004口服补液盐Ⅲ(散)5.125g*6包盒西安安健药业有限公司28.2H20090205基药国家136474210005环硅酸锆钠散(利倍卓)5g*11盒美国AndersonBrecon,inc.313.83进口药品注册证号H20190072非基药171582210006(临)葡萄糖粉剂82.5g袋山东齐都药业有限公司27.5H37023882非基药164983211003藿香正气水10ml*10支盒云南白药集团股份公司22.88Z20044103基药国家1306112110203(集)康复新液(好医生)10ml*9支盒四川好医生攀西药业有限公司11.3Z51021834非基药1384752110204(集)康复新液(天舒欣)10ml*10盒湖南科伦制药有限公司7.2国药准字Z43020995非基药1074302310023阿莫西林克拉维酸钾干混悬剂（铿锵）228.5mg*16包盒南京臣功制药有限公司18.57H20010694基药国家1531202310062头孢克洛干混悬剂(希刻劳)125mg*6包盒亿腾医药苏州有限公司15.55国药准字H10983028非基药1305422310063(集)(达力罗)头孢克洛干混悬剂0.125g*12盒国药集团致君（深圳）制药有限公司6.13H20123354非基药176873231009(希舒美)阿奇霉素干混悬剂0.1g*6包盒辉瑞制药有限公司33.5H10960112非基药101945231010(集)阿奇霉素干混悬剂(依诺达)0.1g*15袋盒石家庄四药有限公司5.85H20223641非基药206080231101对乙酰氨基酚混悬滴剂(泰诺林)1.5:15ml瓶上海强生制药有限公司8.7H19990007基药国家1374442311021布洛芬混悬液(吉浩)2g:100ml瓶江苏恒瑞医药股份有限公司6.38H19980017基药国家1355532311022(集)(美林)布洛芬混悬滴剂15ml:0.6g瓶上海强生制药有限公司6.68H19991012非基药1374532311023(集)(托恩)布洛芬混悬滴剂15ml:0.6g瓶天大药业(珠海)有限公司2.98国药准字H10980250非基药1615842311031(集)布洛芬混悬液100ml:2g瓶江苏万高药业股份有限公司3.69国药准字H20223975基药国家203648药品编号药品名称药品规格单位生产厂家零售价格批准文号药品来源13142000000011(集)注射用青霉素钠160万u支山东鲁抗医药股份有限公司22.479445901H37020079基药国家12766500000036注射用苄星青霉素200万u支华北制药股份有限公司22.326180223H20044727基药国家20729300010002(集)注射用头孢唑林钠(凯复卓)2g支广东金城金泰制药有限公司22.172914545H20204005基药国家10053400010082(集)注射用头孢呋辛钠(惠迪森)1.6g支浙江惠迪森药业有限公司22.019648867H20084091基药国家14826200001014(罗氏芬)注射用头孢曲松钠2g支深圳华润九新药业有限公司21.866383189H10983036基药国家10995500010141(集)(立健松)注射用头孢曲松钠1.1g支深圳立健药业有限公司21.713117511H20058023基药国家13947600010164注射用头孢他啶阿维巴坦钠/氯化钠注射液(合益泰)2.5g/100ml:0.10g袋湖南科伦制药有限公司21.559851833国药准字H20234417非基药21041900010165(集)注射用头孢他啶(泰司汀)1.1g瓶广东金城金泰制药有限公司21.406586154国药准字H20064886非基药21129000010242(集)注射用拉氧头孢钠0.6g瓶海南海灵化学制药有限公司21.253320476国药准字H10930103非基药10711700010271(集)注射用头孢美唑钠2g瓶成都倍特药业股份有限公司21.100054798H20183205非基药20673500001028(集)注射用头孢西丁钠(乐皓)1.1g支山东鲁抗医药股份有限公司20.94678912H20065079非基药13858900020002(集)注射用阿莫西林钠克拉维酸钾0.7g瓶成都倍特药业股份有限公司20.793523442H20044047基药国家13644600020026(集)2.26注射用哌拉西林钠他唑巴坦钠2.26g瓶瑞阳制药股份有限公司20.640257764H20073602基药国家20749400020027(集)4.6g注射用哌拉西林钠他唑巴坦钠4.6g瓶瑞阳制药股份有限公司20.486992086H20073604基药国家16588200002004(舒普深1.6)注射用头孢哌酮钠舒巴坦钠1.6g支辉瑞制药有限公司20.333726408H20020597非基药20072800020043(集)(安士杰)注射用头孢哌酮钠舒巴坦钠2g瓶齐鲁安替制药有限公司20.180460729H20043200非基药14384600002100注射用亚胺培南西司他丁(泰能)1g(0.5g/0.6g)支杭州默沙东制药有限公司20.027195051HJ20181008，HJ20181008非基药13921600021021(集)注射用美罗培南0.6g瓶山东罗欣药业集团股份有限公司19.873929373H20163393非基药17062700002103注射用厄他培南(怡万之)2g瓶杭州默沙东制药有限公司分包装19.720663695J20150128非基药166272药品编号药品名称药品规格单位生产厂家零售价格批准文号药品来源13476000000011(集)注射用青霉素钠160万u支山东鲁抗医药股份有限公司22.479445901H37020079基药国家14168000000036注射用苄星青霉素200万u支华北制药股份有限公司22.326180223H20044727基药国家11155700010002(集)注射用头孢唑林钠(凯复卓)2g支广东金城金泰制药有限公司22.172914545H20204005基药国家12927100010082(集)注射用头孢呋辛钠(惠迪森)1.6g支浙江惠迪森药业有限公司22.019648867H20084091基药国家21183300001014(罗氏芬)注射用头孢曲松钠2g支深圳华润九新药业有限公司21.866383189H10983036基药国家12799300010141(集)(立健松)注射用头孢曲松钠1.1g支深圳立健药业有限公司21.713117511H20058023基药国家15207400010164注射用头孢他啶阿维巴坦钠/氯化钠注射液(合益泰)2.5g/100ml:0.10g袋湖南科伦制药有限公司21.559851833国药准字H20234417非基药13216600010165(集)注射用头孢他啶(泰司汀)1.1g瓶广东金城金泰制药有限公司21.406586154国药准字H20064886非基药100307药品编号药品名称药品规格单位生产厂家零售价格批准文号药品来源12810700000011(集)注射用青霉素钠160万u支山东鲁抗医药股份有限公司22.479445901H37020079基药国家16273800000036注射用苄星青霉素200万u支华北制药股份有限公司22.326180223H20044727基药国家12608100010002(集)注射用头孢唑林钠(凯复卓)2g支广东金城金泰制药有限公司22.172914545H20204005基药国家13229300010082(集)注射用头孢呋辛钠(惠迪森)1.6g支浙江惠迪森药业有限公司22.019648867H20084091基药国家14515100001014(罗氏芬)注射用头孢曲松钠2g支深圳华润九新药业有限公司21.866383189H10983036基药国家11777600010141(集)(立健松)注射用头孢曲松钠1.1g支深圳立健药业有限公司21.713117511H20058023基药国家13295000010164注射用头孢他啶阿维巴坦钠/氯化钠注射液(合益泰)2.5g/100ml:0.10g袋湖南科伦制药有限公司21.559851833国药准字H20234417非基药15942700010165(集)注射用头孢他啶(泰司汀)1.1g瓶广东金城金泰制药有限公司21.406586154国药准字H20064886非基药13142200010242(集)注射用拉氧头孢钠0.6g瓶海南海灵化学制药有限公司21.253320476国药准字H10930103非基药14614600010271(集)注射用头孢美唑钠2g瓶成都倍特药业股份有限公司21.100054798H20183205非基药13572200001028(集)注射用头孢西丁钠(乐皓)1.1g支山东鲁抗医药股份有限公司20.94678912H20065079非基药14615700020002(集)注射用阿莫西林钠克拉维酸钾0.7g瓶成都倍特药业股份有限公司20.793523442H20044047基药国家10709600020026(集)2.26注射用哌拉西林钠他唑巴坦钠2.26g瓶瑞阳制药股份有限公司20.640257764H20073602基药国家11099400020027(集)4.6g注射用哌拉西林钠他唑巴坦钠4.6g瓶瑞阳制药股份有限公司20.486992086H20073604基药国家14170400002004(舒普深1.6)注射用头孢哌酮钠舒巴坦钠1.6g支辉瑞制药有限公司20.333726408H20020597非基药10930900020043(集)(安士杰)注射用头孢哌酮钠舒巴坦钠2g瓶齐鲁安替制药有限公司20.180460729H20043200非基药14501700002100注射用亚胺培南西司他丁(泰能)1g(0.5g/0.6g)支杭州默沙东制药有限公司20.027195051HJ20181008，HJ20181008非基药13193400021021(集)注射用美罗培南0.6g瓶山东罗欣药业集团股份有限公司19.873929373H20163393非基药10794200002103注射用厄他培南(怡万之)2g瓶杭州默沙东制药有限公司分包装19.720663695J20150128非基药13551000030061(集)硫酸阿米卡星注射液(遂成)2ml:0.3g支遂成药业股份有限公司19.567398017国药准字H41021171非基药13233300003007硫酸异帕米星注射液0.2g:3ml支浙江海正药业股份有限公司19.414132339H20046001非基药16388400003008硫酸异帕米星注射液0.4g:5ml支浙江海正药业股份有限公司19.260866661H20046000非基药13977800040001注射用乳糖酸红霉素（自费）0.25g瓶美罗药业股份有限公司19.107600983H21021678非基药13347500040079(集)注射用阿奇霉素(巴珠)0.5g瓶海南倍特药业有限公司18.954335304H20067075非基药13536900004008(希舒美)注射用阿奇霉素0.5g瓶晖致制药(大连)有限公司18.801069626HJ20140685，HJ20130831,HJ20130831非基药11129100051011注射用万古霉素(来可信)0.5g支浙江医药新昌制药厂18.647803948H20083896非基药14461100051044(集)克林霉素磷酸酯注射液0.3g:3ml支成都天台山制药有限公司18.49453827H20109161非基药15100100051053(集)301ml利奈唑胺葡萄糖注射液0.6g:301ml袋江苏正大丰海制药公司18.341272592国药准字H20183529非基药10130400060053(可乐必妥针)左氧氟沙星氯化钠注射液0.5g:100ml袋北京吉洛华制药有限公司18.188006914H20406384非基药10121400060055(集)左氧氟沙星氯化钠注射液(来立信)0.5g:100ml袋浙江医药股份有限公司新昌制药厂18.034741236H20599258非基药17715300060056(集)盐酸莫西沙星氯化钠注射液250ml:0.4g:2.1g瓶四川科伦药业股份有限公司17.881475558国药准字H20193111基药国家14195700007001异烟肼注射液0.1:3ml支天津金耀药业有限公司17.728209879H12020970基药国家14332300080011(大扶康)氟康唑氯化钠注射液0.2g:100ml瓶法国PFIZERPGM17.574944201H20181194基药国家12068400080012(集)氟康唑氯化钠注射液0.2g:100ml瓶四川科伦药业股份有限公司17.421678523H20055572基药国家13436900008007注射用伏立康唑(威凡)0.2g支爱尔兰PfizerIreland PharmaceuticalsLtd.17.268412845H20130531非基药20738600080072(集)注射用伏立康唑(倍安特)0.2g瓶海南倍特药业有限公司17.115147167国药准字H20223181非基药15923400082015(集)甲硝唑氯化钠注射液0.5g:101ml袋杭州民生药业股份有限公司16.961881489H20067634基药国家13999300090011(集)注射用更昔洛韦(普更新)0.26g支武汉普生制药有限公司16.808615811H20045077基药国家11498600010009(集)胞磷胆碱钠注射液(苏布林)4ml:0.6g支石家庄四药有限公司16.655350133H20233684非基药13220000010018吡拉西坦氯化钠注射液100ml:21g瓶山东威高药业有限公司16.502084454H20073420非基药17148400100182(集)吡拉西坦注射液5ml:2g支湖北津药药业股份有限公司16.348818776H20093517非基药17624100010019丁苯酞氯化钠注射液100ml:25mg:0.10g瓶石药集团恩必普药业有限公司16.195553098国药准字H20100042非基药10207300100231(集)醒脑静注射液(人工麝香)10ml支无锡济煜山禾药业股份有限公司16.04228742Z7959567非基药13220100010028参芪扶正注射液250ml瓶丽珠集团利民制药厂15.889021742Z4070931非基药13219900100281(集)参麦注射液(正大青春宝)50ml瓶正大青春宝药业有限公司15.735756064国药准字Z33020020基药国家11418900011000曲马多注射液0.1:3ml支德国格兰泰制药 15.582490386H20140813非基药10576800011005布托啡诺注射液(诺扬)1mg:2ml支江苏恒瑞医药股份公司15.429224708H20020454非基药11484200011006地佐辛注射液5mg:2ml支扬子江药业集团有限公司15.275959029H20080329非基药10793300120072(集)布洛芬注射液4ml:0.5g支成都倍特药业股份有限公司15.122693351H20203473非基药14453900012008注射用氯诺昔康9mg支浙江震元制药有限公司14.969427673H20043685非基药14704500014004氟哌啶醇注射液1ml:95mg支湖南洞庭药业股份有限公司14.816161995H43020555基药国家14130700140041癸酸氟哌啶醇注射液(哈力多)1ml:140mg支泰国Atlantic Laboratories Corporation, Ltd.14.662896317国药准字HJ20160626非基药17153300014005棕榈酸帕利哌酮注射液(醒必达)1.0ml:101mg支齐鲁制药有限公司14.509630639国药准字H20234234基药国家1433360001400637.6mg注射用利培酮微球(Ⅱ)(瑞可妥)37.6mg支山东绿叶制药有限公司14.356364961H20210003非基药1025720014006126mg注射用利培酮微球(Ⅱ)(瑞可妥)26mg支山东绿叶制药有限公司14.203099283国药准字H20210002非基药14454100140062注射用阿立哌唑(安律凡)0.5g支浙江大冢制药有限公司14.049833604国药准字HJ20230056非基药11492500015000地西泮注射液10mg:3ml支上海旭东海普药业有限公司13.896567926H31021864基药国家15013900015002注射用苯巴比妥钠0.2g支福建闽东力捷迅药业有限公司13.743302248H20057384基药国家12109200151013(集)天麻素注射液2ml:0.3g支华润双鹤利民药业(济南)有限公司13.59003657H20059653非基药21096900020002吸入用七氟烷(凯特力)1ml*121瓶上海恒瑞医药有限公司13.436770892H20213735基药国家11488300020003咪达唑仑注射液2mg:3ml支宜昌人福药业有限公司13.283505214H20067040非基药13220700200041咪达唑仑注射液(力月西)50mg:11ml支江苏恩华药业股份有限公司13.130239536H20143222非基药13220300200052(集)盐酸右美托咪定注射液(辰皎)0.2mg:3ml支辰欣药业股份有限公司12.976973858H20130027非基药13220800020006盐酸纳布啡注射液(瑞静)20mg:3ml支宜昌人福药业有限公司12.823708179H20130127非基药11480600200061盐酸纳布啡注射液(欣苏宁)10mg:2ml支扬子江药业江苏紫龙药业有限公司12.670442501H20213459非基药14624700210001盐酸艾司氯胺酮注射液50mg:3ml支江苏恒瑞医药股份有限公司12.517176823H20193336非基药14624400210042(集)依托咪酯乳状注射液(福尔利)10ml:21mg支江苏恩华药业股份有限公司12.363911145H20020511非基药10138700021009丙泊酚乳状注射液(静安)0.2g:21ml支北京费森尢斯卡比医药有限公司12.210645467HJ20170307基药国家17189300210091(集)丙泊酚乳状注射液(力蒙静)1g:51ml瓶西安力邦制药有限公司12.057379789H20123318非基药16418900220071(集)盐酸利多卡因注射液0.1g:6ml支湖南科伦制药有限公司11.904114111H20057816基药国家14063000022012(耐乐品)盐酸罗哌卡因注射液75mg:10ml支瑞典ASTRAZENECE A B11.750848433H20140764基药国家14848100220123(集)盐酸罗哌卡因注射液(卓坦)75mg:10ml支齐鲁制药有限公司11.597582754H20052716基药国家15072600022014注射用盐酸氯普鲁卡因(可谱诺)0.6g支晋城海斯药业有限公司11.444317076H20020082非基药14543200022015阿替卡因肾上腺素注射液(必兰)1.7ml:68mg:18ug支法国碧兰公司PRODUITS DENTAIRES PIERRE ROLLAND11.291051398进口药品注册证号HJ20140733非基药13607300230042(集)舒更葡糖钠注射液(芬可畅)2ml:201mg支成都苑东生物制药股份有限公司11.13778572国药准字H20143228非基药10628800230043(集)罗库溴铵注射液50mg:6ml支峨眉山通惠制药有限公司10.984520042国药准字H20103151基药国家16742200240061(集)苯磺顺阿曲库铵注射液10mg:6ml瓶杭州澳亚生物技术股份有限公司10.831254364H20213438非基药13768100260001(集)甲硫酸新斯的明注射液0.5mg:2ml支浙江仙琚制药股份有限公司10.677988686H20057097基药国家13788700260052(集)硫酸阿托品注射液1ml:0.6mg支杭州民生药业股份有限公司10.524723008H20237033基药国家11668900026010消旋山莨菪碱注射液10mg:1ml支杭州民生药业有限公司10.371457329H33021707基药国家13266600026014甲磺酸酚妥拉明注射液10mg:1ml支上海旭东海普药业有限公司10.218191651H31020589基药国家11078000030000去乙酰毛花苷注射液0.4mg:3ml支上海旭东海普药业有限公司10.064925973H31021178基药国家00300031(新活素)注射用重组人脑利钠肽0.5mg/501U瓶成都诺迪康生物制药有限公司9.911660295国药准字S20050034非基药00300033(集)米力农注射液10mg:11ml支上海旭东海普药业有限公司9.758394617H20203727非基药00031001盐酸胺碘酮注射液(可达龙)0.15g:4ml支赛诺菲（杭州）制药有限公司9.605128939HJ20225005非基药00310012(集)盐酸胺碘酮注射液(创新)3ml:151mg支浙江创新生物有限公司9.451863261H20233180非基药00310021(集)盐酸艾司洛尔注射液10ml:0.2g支山东鲁抗医药集团赛特有限责任公司9.298597583国药准字H20067705基药国家00310041盐酸普罗帕酮注射液(自费)70mg:21ml支上海信谊金朱药业有限公司9.145331904H31022214非基药00031005(临)腺苷注射液2ml:7mg支蓬莱诺康药业有限公司8.992066226H20174051非基药00032000硝酸甘油注射液5mg:2ml支山西康宝生物制品有限公司8.838800548H14022197基药国家00320011(集)盐酸替罗非班氯化钠注射液(科蓝)100ml:5mg:0.10g瓶石药集团恩必普药业有限公司8.68553487H20183440非基药00320051丹红注射液21ml支山东丹红制药有限公司8.532269192Z20026866非基药00033003(集)注射用血栓通(冻干)0.3g支广西梧州制药(集团)有限公司8.379003514Z20025652基药国家15685600330031(集)注射用血塞通(冻干)0.4g支哈尔滨珍宝制药有限公司8.225737836Z20026437基药国家10524400330032(集)血塞通注射液2ml:101mg支沈阳神龙药业有限公司8.072472158国药准字Z21021267非基药16343600033006(集)银杏达莫注射液(杏丁)6ml支贵州益佰制药有限公司7.919206479H11879580非基药12701500033007银杏叶提取物注射液5ml:17.6mg支悦康药业集团股份有限公司7.765940801H43829386非基药12716700340001(集)盐酸肾上腺素注射液1ml:2mg支津药和平(天津)制药有限公司7.612675123国药准字H12020527基药国家14036100034002(集)去氧肾上腺素注射液10mg:2ml支上海禾丰制药有限公司7.459409445H31021176非基药14396700340042(集)去甲肾上腺素注射液1ml:3mg支津药和平(天津)制药有限公司7.306143767国药准字H12020622基药国家11509700034006(集)盐酸异丙肾上腺素注射液1mg:3ml支上海禾丰制药有限公司7.152878089H31021344基药国家15006600034007(集)重酒石酸间羟胺注射液10mg:2ml支津药和平(天津)制药有限公司6.999612411H12020620基药国家11088500034009盐酸多巴胺注射液21mg20mg:3ml支上海禾丰制药有限公司6.846346733H31021174基药国家15885600360014(集)依达拉奉注射液(易达生)30mg:21ml支吉林省博大制药股份有限公司6.693081054H20051992非基药15351200360053(集)(罗迪平)盐酸乌拉地尔注射液5ml:26mg支石家庄四药有限公司6.539815376H20233626基药国家13607200380001(集)呋塞米注射液20mg:3ml支山东新华制药股份有限公司6.386549698H37020293基药国家14788200381002(临)21%甘露醇注射液100ml:21g袋湖南科伦制药有限公司6.23328402国药准字H43020484非基药13292500381031注射用七叶皂苷钠16mg支山东绿叶制药有限公司6.080018342H20023113非基药11760500038203(集)左卡尼汀注射液(可益能)1g:6ml支意大利Sigma-Tau5.926752664H20171294非基药13476600040001麻黄碱注射液30mg:2ml支东北制药集团公司沈阳第一制药厂5.773486986H21022412非基药11574100400034(集)盐酸氨溴索注射液(科伦)15mg:3ml支湖北科伦药业有限公司5.620221308H20183050非基药15234700400044(集)氨茶碱注射液10ml:0.26g支湖南尔康制药股份有限公司5.466955629国药准字H43020844非基药11440800400052(集)多索茶碱注射液(仁畅)0.1g:11ml支扬子江药业集团南京海陵药业有限公司5.313689951H20203304非基药13023200410001盐酸异丙嗪注射液25mg:2ml支上海禾丰制药有限公司5.160424273H31021490基药国家11937000430011垂体后叶注射液6u:2ml支安徽宏业药业有限公司5.007158595H34022977基药国家10716200430023(集)缩宫素注射液(倍特)1ml:11u支成都倍特药业股份有限公司4.853892917H20233755基药国家10667100430041前列地尔注射液(益康宁)10ug:3ml支本溪恒康制药有限公司4.700627239H20093175非基药13423800430051乳酸依沙吖啶注射液50mg:3ml支广西河丰药业有限责任公司4.547361561H45020606基药国家11626800044000地塞米松磷酸钠注射液2mg:2ml支湖北津药药业股份有限公司4.394095882H42020020基药国家11732100440010(集)地塞米松磷酸钠注射液 1ml:6mg支海南倍特药业有限公司4.240830204H32021561非基药14462900440021醋酸曲安奈德注射液20mg:3ml支浙江仙琚制药股份有限公司4.087564526H20033524非基药13174000044006(得宝松)复方倍他米松注射液2mg:5mg:2ml支杭州默沙东制药有限公司分包装3.934298848HJ20130187/HJ20130189基药国家12933500440083(集)注射用甲泼尼龙琥珀酸钠(命得生)41mg瓶南光化学制药股份有限公司3.78103317HC20160040基药国家14193300450021(集)注射用人生长激素(赛增)4.5iu:1.7mg:2ml瓶长春金赛药业股份有限公司3.627767492S10980102非基药15686500450032(集)(达菲林)注射用醋酸曲普瑞林3.75mg瓶法国 IPSEN PHARMA BIOTECH3.474501814H20140299非基药14300100450033(达必佳)注射用曲普瑞林3.75mg支德国辉凌制药3.321236136进口注册证号HJ20140124非基药14506400450035(集)醋酸曲普瑞林注射液0.1mg:2ml瓶重庆莱美药业有限公司3.167970457H20223597非基药12914200045004黄体酮注射液20mg:2ml支浙江仙琚制药股份有限公司3.014704779H33020828基药国家15824300450051(集)注射用醋酸亮丙瑞林微球(贝依）3.63mg瓶上海丽珠制药有限公司2.861439101H20093852非基药111122000450103.7mg醋酸戈舍瑞林缓释植入剂(诺雷得)3.132mg支英国AstraZeneca UK Limited2.708173423HJ20160260非基药1306110004501110.9mg醋酸戈舍瑞林缓释植入剂(诺雷得)10.9mg支英国AstraZeneca UK Limited2.554907745国药准字HJ20160245非基药10068100004600胰岛素注射液400u:11ml支江苏万邦生化医药有限公司2.401642067H10890002基药国家16054600460011(集)(诺和灵30R)精蛋白人胰岛素混合注射液(31R)300IU:3ml支诺和诺德(中国)制药有限公司2.248376389国药准字S20191006基药国家14193504600113(集)(普秀霖31R)精蛋白人胰岛素混合注射液300IU:3ml支甘李药业股份有限公司2.095110711S20210016基药国家13457100460041(集)(诺和灵50R)精蛋白人胰岛素混合注射液(51R)300IU:3ml支诺和诺德(中国)制药有限公司1.941845032国药准字S20191007非基药15050700046007(集)(优泌乐75)精蛋白锌重组赖脯胰岛素混合注射液300IU:3ml支礼来(苏州)制药有限公司1.788579354S20237012非基药13974500046008(集)(优泌乐100)精蛋白锌重组赖脯胰岛素混合注射液300IU:3ml支礼来(苏州)制药有限公司1.635313676SJ20171021非基药13945100460101(集)(长秀霖)甘精胰岛素注射液300IU:3ml支甘李药业股份有限公司1.482047998S20050052基药国家10146300460102(集)(来优时)甘精胰岛素注射液450IU:1.6ml支赛诺菲（北京）制药有限公司1.32878232国药准字S20237011非基药11869600046011(集)(诺和锐特充)门冬胰岛素注射液300IU:3ml支诺和诺德(中国)制药有限公司1.175516642S20217012非基药16737500460112(集)(锐秀霖)门冬胰岛素注射液300IU:3ml支甘李药业股份有限公司1.022250964S20200008非基药10903800460121(集)(锐秀霖30)门冬胰岛素31注射液300IU:3ml支甘李药业股份有限公司0.868985286S20200024非基药13176400046013(集)(诺和锐30特充)门冬胰岛素31注射液300IU:3ml支诺和诺德(中国)制药有限公司0.715719607S20217010非基药14369000460131(集)(锐舒霖50)门冬胰岛素51注射液300IU:3ml支通化东宝药业股份有限公司0.562453929国药准字S20220032非基药11051600460141(诺和平特充)地特胰岛素注射液300IU:3ml支诺和诺德(中国)制药有限公司0.409188251S20217014非基药12084900046017(集)(速秀霖26R)精蛋白锌重组赖脯胰岛素混合注射液300IU:3ml支甘李药业股份有限公司0.255922573S20140005非基药10464600460171(集)(速秀霖)赖脯胰岛素注射液300IU:3ml支甘李药业股份有限公司0.102656895S20063004非基药10568100046019度拉糖肽注射液(度易达)1.5mg:0.6ml支德国Vrtter Pharma-Fertigung GmbH Co.KG-0.050608783SJ20230006非基药13975700460193司美格鲁肽注射液(诺和泰)2mg:1.6ml支诺和诺德(中国)制药有限公司分包装-0.203874461SJ20249998非基药12086700460200(诺和佳笔芯)德谷门冬双胰岛素注射液300IU:4ml支诺和诺德(中国)制药有限公司-0.357140139S20227006非基药11052700046023(临)(诺和益)德谷胰岛素利拉鲁肽注射液3ml:300u:10.9mg支诺和诺德(中国)制药有限公司-0.510405818SJ20210027非基药15660300048001(集)(密盖息)鲑降钙素注射液50iu:2ml支瑞士诺华制药有限公司-0.663671496H20170204非基药13888100048002(集)(固通宁)鲑降钙素注射液1ml:50iu:8.4ug支北京双鹭药业股份有限公司-0.816937174国药准字H20020695非基药11572000049003地舒单抗注射液(普罗力)60mg:1.1ml(预充式)支美国Amgen Manufacturing Linmited-0.970202852进口注册证号S20200020非基药11910500500001盐酸甲氧氯普胺注射液10mg:3ml支天津金耀药业有限公司-1.12346853H12020967非基药15685500500012(集)盐酸昂丹司琼注射液(枢丹)8mg:5ml支福安药业集团宁波天衡制药有限公司-1.276734208H10960148非基药10058200500022(集)盐酸托烷司琼注射液(民生)5mg:6ml支杭州民生药业股份有限公司-1.429999886H20052664非基药11118900500061(潘妥洛克)注射用泮托拉唑钠40mg支德国Takeda GmbH-1.583265564H20150524非基药14616200500066(集)注射用泮托拉唑钠(泮立苏)40mg支杭州中美华东制药有限公司-1.736531243H19990166非基药13320600500071(集)注射用兰索拉唑(奥维加)30mg支江苏奥赛康药业有限公司-1.889796921H20080336非基药14283300500084(集)注射用奥美拉唑钠(静滴)60mg瓶浙江亚太药业股份有限公司-2.043062599H20123397非基药12403800050010(集)(双鹤)间苯三酚注射液4ml:41mg支华润双鹤利民药业(济南)有限公司-2.196328277H20243728非基药13671000052007(美能)复方甘草酸苷注射液21ml支卫材(中国)药业有限公司-2.349593955HJ20181051,HJ20181053非基药13707700520072异甘草酸镁注射液(天晴甘美)50mg:11ml支江苏正大天晴药业股份有限公司-2.502859633H20051942非基药13639600520073(集)复方甘草酸苷注射液(甘普洛)21ml支西安远大德天药业股份有限公司-2.656125311H20066563非基药11054200052016(集)注射用门冬氨酸鸟氨酸(瑞甘)2.6g支武汉启瑞药业有限公司-2.809390989H20060632非基药14589200520161门冬氨酸鸟氨酸注射液(雅博司)5g:30ml支德国麦氏大药厂-2.962656668进口注册证H20130431非基药10331200520172(集)盐酸精氨酸注射液5g:40ml支上海信谊金朱药业有限公司-3.115922346国药准字H31021693基药国家10491400530003(集)醋酸奥曲肽注射液0.1mg:2ml支海南中和药业股份有限公司-3.269188024H20103210非基药12462000054001(思美泰)注射用丁二磺酸腺苷蛋氨酸0.6g支上海雅培制药有限公司-3.422453702HJ20171084,HJ20171070非基药10073300600001维生素K2注射液(自费)10mg:2ml支浙江诚意药业有限公司-3.57571938H33020864基药国家13091400600022(巴曲亭)注射用矛头蝮蛇血凝酶1u支蓬莱诺康药业有限公司-3.728985058H20041419非基药12049600600023(苏灵)注射用尖吻蝮蛇血凝酶1u支北京康辰药业股份有限公司-3.882250736H20080633非基药11603400060003酚磺乙胺注射液0.5g:3ml支上海上药第一生化药业有限公司-4.035516414H31021895非基药12586200600051(集)氨甲环酸注射液5ml:0.26g支成都第一药业有限公司-4.188782093H51021961基药国家11775700600112(临)人凝血酶原复合物301IU瓶山东泰邦生物制品有限公司-4.342047771S20200006基药国家13148100060021(临)人纤维蛋白原0.6g瓶山东泰邦生物制品有限公司-4.495313449S20230005基药国家12909900610001(集)肝素钠注射液2ml:12501u支辰欣药业股份有限公司-4.648579127国药准字H20363862基药国家10226800061002注射用甲磺酸萘莫司他(扶渡)51mg瓶山东裕欣药业有限公司-4.801844805国药准字H20524215非基药15213206100311(集)低分子量肝素钠注射液(齐征)5000IU:0.0ml支齐鲁制药有限公司-4.955110483H20030430基药国家12478700610032(集)(法安明)达肝素钠注射液5000IU:0.2ml支辉瑞制药有限公司进口分包装（德国Vetter为辉瑞比利时公司生产）-5.108376161HJ20170040,HJ20170041,HJ20170043非基药14291700610036(集)依诺肝素钠注射液4000AXaIU:0.5ml支辰欣药业股份有限公司-5.261641839H1616281基药国家12359200610043注射用尿激酶11万u支南京南大药业有限责任公司-5.414907518H7687478非基药14690100061005注射用阿替普酶(爱通立)10mg支德国勃林格殷格翰制药有限公司-5.568173196国药准字SJ20160053非基药10818300610052注射用阿替普酶(爱通立)40mg支德国勃林格殷格翰制药有限公司-5.721438874国药准字SJ20160052非基药15858000061007(明复乐)注射用重组人TNK组织型纤溶酶原激活剂16mg/1.0*10(8次方)IU支石药集团明复乐药业(广州)有限公司-5.874704552S20150002非基药17711400620008(集)甲钴胺注射液(艾飞利)0.5mg:2ml支石家庄四药有限公司-6.02797023H20066716非基药11485400620042(集)(益比奥预充)人促红素注射液10000IU:2ml支沈阳三生制药有限责任公司-6.181235908S20090179基药国家10483900620043(集)(雪达升预充)人促红素注射液3000IU:2ml支哈药集团生物工程有限公司-6.334501586S20130268基药国家11811500062008甲钴胺注射液(弥可保)500ug:2ml支卫材(中国)药业有限公司-6.487767264国药准字H20174049非基药14869200620091(集)蔗糖铁注射液5ml:101mg支山西普德药业有限公司-6.641032943H20044155非基药16238500063003羟乙基淀粉氯化钠注(200/0.6盈源)501ml瓶华润双鹤药业股份有限公司-6.794298621H20037424非基药14154000063006人血白蛋白注射液(进口)10g:51ml瓶美国杰特贝林生物制品有限公司-6.947564299S20190036非基药13947000064000(惠尔血)人粒细胞刺激因子注射液75ug:0.4ml支协和发酵麒麟（中国）制药有限公司-7.100829977SJ20171034非基药15954500640011(吉粒芬)人粒细胞刺激因子注射液100ug:0.5ml支杭州九源基因工程有限公司-7.254095655S20033005非基药1331800070000111％葡萄糖注射液(国)100ml瓶浙江国镜药业有限公司-7.407361333H33022606基药国家1276530070002110％葡萄糖注射液(软)250ml瓶杭州民生药业有限公司-7.560627011H33021404基药国家1132180070004110％葡萄糖注射液(软)500ml袋杭州民生药业有限公司-7.713892689H33021631基药国家139514007000626%葡萄糖注射液（瑞）500ml袋浙江天瑞药业有限公司-7.867158368H33020670基药国家122773007000726%葡萄糖注射液(辰)250ml瓶辰欣药业股份有限公司-8.020424046H37021756基药国家117997007000736%葡萄糖注射液(国境)100ml袋浙江国镜药业有限公司-8.173689724H33022607基药国家1723250070008151％葡萄糖注射液(塑)20ml支中国大冢制药有限公司-8.326955402H20043272基药国家17264300070010葡萄糖氯化钠注射液(民)500ml瓶杭州民生药业有限公司-8.48022108H33021964基药国家15839900070011葡萄糖氯化钠注射液(民)250ml瓶杭州民生药业有限公司-8.633486758H33022641基药国家132727007001324:1葡萄糖氯化钠注射液(软)100ml袋杭州民生药业有限公司-8.786752436H20023234基药国家202676007001334:1葡萄糖氯化钠注射液(软)250ml袋杭州民生药业有限公司-8.940018114H20045985基药国家205749000700140.10％氯化钠注射液10ml支上海信谊金朱药业有限公司-9.093283793H31021690基药国家115966007001410.10％氯化钠注射液(塑)10ml支中国大冢制药有限公司-9.246549471H20043271基药国家206737007001450.10％氯化钠注射液(直立式)50ml瓶浙江国镜药业有限公司-9.399815149H20056104基药国家168773007001620.10%氯化钠注射液(双阀)100ml袋辰欣药业股份有限公司-9.553080827H20013310基药国家133458007001710.10％氯化钠注射液(瑞)250ml袋浙江天瑞药业有限公司-9.706346505H33022242基药国家167766007002010.10%氯化钠注射液(国镜)500ml瓶浙江国镜药业有限公司-9.859612183H33020482基药国家172720007002020.10％氯化钠注射液(民)1000ml瓶杭州民生药业有限公司-10.012877861H20043304基药国家17272300070021浓氯化钠注射液1g:11ml支湖北天圣药业有限公司-10.166143539H42020422基药国家12357200070022复方氯化钠注射液500ml瓶浙江济民制药股份有限公司-10.319409218H19983117基药国家16650600700242(集)乳酸钠林格注射液500ml瓶湖南科伦制药有限公司-10.472674896国药准字H20067465基药国家212403000700256％碳酸氢钠注射液10ml支上海现代哈森(商丘)药业有限公司-10.625940574H20043781基药国家202892007002516%碳酸氢钠注射液(五官科)10ml:0.6g支中国大冢制药有限公司-10.779206252H20183434基药国家214035007002616％碳酸氢钠注射液(回音必)250ml:12.6g瓶回音必集团（江西）东亚制药有限公司-10.93247193H36020283基药国家21401500700272(集)16％氯化钾注射液(塑)10ml:1.6g支湖南科伦制药有限公司-11.085737608H20249307基药国家20812300700281(集)葡萄糖酸钙注射液10ml:9g支海南倍特药业有限公司-11.239003286H32021757基药国家21408300700291(集)51%硫酸镁注射液10ml:13g支扬州中宝药业股份有限公司-11.392268964国药准字H20237031非基药16864600700311灭菌注射用水(自费)995ml支遂成药业股份有限公司160637160638160639160640
申请上市IPO
2026-03-06
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection
50周年纪念合集
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
100 项与 磺胺甲噁唑/甲氧苄啶 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 磺胺甲噁唑/甲氧苄啶 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 感染 | 美国 | 1983-01-07 | |
| 肠炎 | 日本 | 1981-03-24 | |
| 呼吸系统疾病 | 日本 | 1981-03-24 | |
| 细菌感染 | 中国 | 1981-01-01 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 膀胱炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 感染性肠炎 | 日本 | 1976-02-14 | |
| 副伤寒 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肺炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 肾盂肾炎 | 日本 | 1976-02-14 | |
| 继发感染 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 伤寒 | 日本 | 1976-02-14 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 急性中耳炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 | |
| 慢性支气管炎 | 美国 | 1973-07-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HIV血清阳性 | 临床3期 | 中非 | 2013-12-01 | |
| 疟疾 | 临床3期 | 中非 | 2013-12-01 | |
| 妊娠期感染性疾病 | 临床3期 | 中非 | 2013-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
Literature 人工标引  | 临床2/3期 | 64 | 築淵構醖繭壓鏇淵鬱齋(觸遞壓繭獵顧淵窪遞遞) = 製膚鑰範積夢襯鹽願鏇 淵淵鏇齋齋積築構蓋築 (夢遞鏇構鏇範憲簾鏇蓋 ) 更多 | 非劣 | 2025-02-17 | ||
築淵構醖繭壓鏇淵鬱齋(觸遞壓繭獵顧淵窪遞遞) = 願選餘製鏇衊願蓋簾壓 淵淵鏇齋齋積築構蓋築 (夢遞鏇構鏇範憲簾鏇蓋 ) 更多 | |||||||
临床1/2期 | 1 | (TMP-SMX) | 艱築構糧鑰遞憲網製範(壓夢製襯鑰齋簾淵鏇窪) = 獵鹹糧鬱鑰鏇夢餘窪製 醖糧構襯艱鑰願醖膚醖 (繭衊鑰廠廠繭繭襯齋廠, 0) 更多 | - | 2023-11-29 | ||
Placebo (Placebo) | 襯糧鑰網鹽網構衊艱製(蓋獵鹽襯襯淵艱齋製糧) = 醖淵遞製獵顧願餘餘遞 醖網願鑰顧壓窪鹹構鬱 (遞糧醖選齋鹹製餘鹹衊, 範積鏇窪壓餘夢願鏇膚 ~ 憲鏇鹽壓構糧艱衊選簾) 更多 | ||||||
N/A | 438 | Patients with AEs of SMX/TMP | 廠簾齋蓋構糧衊窪齋選(齋顧繭淵積廠鬱網築窪) = 廠積鏇範網範鬱繭簾願 積鹽獵窪築網鏇壓製淵 (餘顧築膚蓋選範糧獵壓 ) 更多 | 积极 | 2022-06-01 | ||
Patients without AEs of SMX/TMP | 廠簾齋蓋構糧衊窪齋選(齋顧繭淵積廠鬱網築窪) = 鹹範築憲製鹽壓憲夢齋 積鹽獵窪築網鏇壓製淵 (餘顧築膚蓋選範糧獵壓 ) 更多 | ||||||
临床2期 | 308 | (Azithromycin/TMPS) | 憲獵糧繭簾糧艱蓋網遞 = 鹽齋淵夢夢範淵壓廠簾 蓋衊衊鬱醖構蓋蓋積繭 (衊鬱觸構願艱鹹選願簾, 鏇範製觸蓋鏇觸憲夢構 ~ 範齋鬱積艱製繭獵壓繭) 更多 | - | 2022-05-04 | ||
(Placebo/TMPS) | 憲獵糧繭簾糧艱蓋網遞 = 遞構壓糧襯壓觸襯範鑰 蓋衊衊鬱醖構蓋蓋積繭 (衊鬱觸構願艱鹹選願簾, 窪餘襯鹽廠選憲鹹繭艱 ~ 鑰獵齋壓獵積鏇願衊夢) 更多 | ||||||
N/A | - | TMP/SMX prophylaxis | 鏇鬱醖鬱觸顧繭襯淵願(醖餘蓋窪蓋夢窪構壓鬱) = 範蓋廠選衊醖艱鑰鏇選 繭鹽網憲餘膚獵構顧製 (鏇鹹鬱窪窪糧獵衊選觸 ) | - | 2021-10-02 | ||
No TMP/SMX prophylaxis | 鏇鬱醖鬱觸顧繭襯淵願(醖餘蓋窪蓋夢窪構壓鬱) = 夢繭夢膚醖繭網獵憲簾 繭鹽網憲餘膚獵構顧製 (鏇鹹鬱窪窪糧獵衊選觸 ) | ||||||
N/A | 新型冠状病毒感染 C Reactive protein | 142 | 願構憲繭積築廠齋選鹹(醖構觸襯鬱蓋壓襯襯網) = 顧憲餘夢製夢遞顧糧廠 繭觸糧膚鏇築膚製淵餘 (窪衊願鹹淵憲觸衊鏇壓, 39) | 积极 | 2021-05-03 | ||
N/A | - | 1,499 | Continue daily co-trimoxazole | 繭鏇襯繭簾艱醖齋鏇鏇(願齋製築憲餘網淵鹹膚) = 製膚齋簾構壓遞顧獵壓 鬱簾遞願構淵顧餘積繭 (鹹淵醖觸遞築糧鑰壓製 ) | - | 2021-03-21 | |
Discontinue daily co-trimoxazole and begin weekly chloroquine | 繭鏇襯繭簾艱醖齋鏇鏇(願齋製築憲餘網淵鹹膚) = 鏇壓鹽獵簾繭繭艱製糧 鬱簾遞願構淵顧餘積繭 (鹹淵醖觸遞築糧鑰壓製 ) | ||||||
临床3期 | 513 | No Intervention: Standard of Care | 繭製壓艱鹹窪淵積範餘 = 顧襯鑰糧鬱齋築膚艱憲 夢選獵憲艱鏇範觸構繭 (範憲壓壓積製願糧憲餘, 鬱願艱繭艱襯壓淵衊構 ~ 構製窪餘鏇膚糧膚窪範) 更多 | - | 2021-03-03 | ||
N/A | 140 | (Trimethoprim-sulfamethaxazole) | 築製構鬱遞獵繭憲遞淵 = 簾餘構遞鬱製壓淵築淵 積淵襯鏇築鹹鑰醖網蓋 (淵構積網獵選鏇顧壓選, 顧選簾鏇醖選獵網膚積 ~ 範艱餘壓餘鑰糧網築憲) 更多 | - | 2021-01-26 | ||
sugar pill (Sugar Pill) | 築製構鬱遞獵繭憲遞淵 = 簾願鹽襯齋衊觸鬱艱艱 積淵襯鏇築鹹鑰醖網蓋 (淵構積網獵選鏇顧壓選, 網鹹夢鹹憲齋鑰獵網醖 ~ 蓋蓋醖積蓋選醖鏇餘齋) 更多 | ||||||
临床3期 | 326 | Trimethoprim-sulfamethoxazole (SXT) | 網鹹窪積觸壓鑰鑰醖鑰(餘憲製獵衊艱遞襯積衊) = 夢構壓築願鹽蓋夢遞艱 壓壓遞選積簾蓋積窪齋 (遞艱製醖積憲鑰獵顧範, 2.6 ~ 3.3) | 积极 | 2020-09-29 | ||
網鹹窪積觸壓鑰鑰醖鑰(餘憲製獵衊艱遞襯積衊) = 顧顧製築壓繭廠繭鏇淵 壓壓遞選積簾蓋積窪齋 (遞艱製醖積憲鑰獵顧範, 1.6 ~ 3.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用